NZ617446B2 - Anti-nerve growth factor antibodies and methods of preparing and using the same - Google Patents
Anti-nerve growth factor antibodies and methods of preparing and using the same Download PDFInfo
- Publication number
- NZ617446B2 NZ617446B2 NZ617446A NZ61744612A NZ617446B2 NZ 617446 B2 NZ617446 B2 NZ 617446B2 NZ 617446 A NZ617446 A NZ 617446A NZ 61744612 A NZ61744612 A NZ 61744612A NZ 617446 B2 NZ617446 B2 NZ 617446B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- canine
- amino acid
- ngf
- antibodies
- Prior art date
Links
- 229940053128 nerve growth factor Drugs 0.000 title claims abstract description 169
- 238000000034 method Methods 0.000 title claims abstract description 91
- 241000282465 Canis Species 0.000 claims abstract description 171
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract description 168
- 230000027455 binding Effects 0.000 claims abstract description 168
- 102000015336 Nerve Growth Factor Human genes 0.000 claims abstract description 166
- 239000012634 fragment Substances 0.000 claims abstract description 80
- 150000001413 amino acids Chemical class 0.000 claims abstract description 76
- 239000000427 antigen Substances 0.000 claims abstract description 40
- 102000036639 antigens Human genes 0.000 claims abstract description 40
- 108091007433 antigens Proteins 0.000 claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 101150111783 NTRK1 gene Proteins 0.000 claims abstract description 8
- 108091008604 NGF receptors Proteins 0.000 claims abstract description 4
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 107
- 125000000539 amino acid group Chemical group 0.000 claims description 47
- 241000894007 species Species 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 description 86
- 229940024606 amino acid Drugs 0.000 description 74
- 208000002193 Pain Diseases 0.000 description 66
- 230000036407 pain Effects 0.000 description 55
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 150000002500 ions Chemical class 0.000 description 29
- 230000003472 neutralizing effect Effects 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 241000282472 Canis lupus familiaris Species 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 23
- 230000000295 complement effect Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
- 239000013598 vector Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 239000012636 effector Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 208000000094 Chronic Pain Diseases 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 238000005571 anion exchange chromatography Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 208000004296 neuralgia Diseases 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- -1 such as an antibody Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010065390 Inflammatory pain Diseases 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000030175 lameness Diseases 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 6
- 208000004550 Postoperative Pain Diseases 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013019 capto adhere Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 102000015533 trkA Receptor Human genes 0.000 description 5
- 108010064884 trkA Receptor Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012829 orthopaedic surgery Methods 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001823 pruritic effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N L-Theanine Natural products CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 244000122871 Caryocar villosum Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710113304 Glutathione S-transferase class-mu 28 kDa isozyme Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 101000985498 Mus musculus Hermansky-Pudlak syndrome 4 protein homolog Proteins 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 101710088929 Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 1
- 229960002524 firocoxib Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Disclosed is an antibody or an antigen binding fragment thereof which is capable of specifically binding to canine nerve growth factor (NGF) and inhibiting the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor, wherein the antibody or antigen binding fragment comprises the heavy and light chains of the sequences as disclosed in the specification; wherein the antibody or antigen binding fragment thereof does not contain any amino acid in any position within the framework regions which would be foreign at the position in one or more canine antibodies. Also disclosed is a method for preparing such antibodies nd light chains of the sequences as disclosed in the specification; wherein the antibody or antigen binding fragment thereof does not contain any amino acid in any position within the framework regions which would be foreign at the position in one or more canine antibodies. Also disclosed is a method for preparing such antibodies
Description
ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF
ING AND USING THE SAME
Field of the Invention
The present invention relates to antibodies, and fragments thereof, which act as
antagonists of canine nerve growth factor. The invention extends to methods of
preparing same and to the therapeutic use of these antibodies and fragments in
treating conditions associated with nerve growth factor such as pain, pain d
disorders and conditions which result in the occurrence of chronic pain in canines.
ound to the ion
Nerve growth factor (NGF) is a naturally occurring secreted n which consists
of an alpha, beta and gamma polypeptide chain. NGF is a member of the
neurotrophin family and is implicated in a number ofdifferent roles. NGF
promotes survival and entiation of sensory and sympathetic s and
s via two membrane bound receptors, p75, a low affinity NGF receptor and
TrkA, a transmembrane tyrosine kinase and a high affinity NGF receptor. The
binding of NGF to TrkA or p75 results in an upregulation of neuropeptides in
sensory neurons.
The use of NGF antagonists to treat pain and pain sensitivity in humans has been
described (Cattaneo A., Curr. Op. Mol. Ther. 2010 12(1):94-106). For example,
ational Patent Application No. describes a humanised
form of the rat alphaD11 (dD11, aD11) monoclonal antibody. The (IBM antibody
has binding specificity to mouse NGF, but is also known to bind to human and rat
forms of NGF. Humanisation of the aD11 rat derived monoclonal antibody is
required prior to administration to humans in order to minimise the production of
neutralising antibodies which result from a human anti-mouse antibody (HAMA)
response being d against rodent derived antibodies. Furthermore, the
replacement of mouse constant domains with human constant domains allows
downstream effector functions to be selected for.
Pain management in canines is currently provided through administration of
analgesic drugs of several s, including local and general anaesthetics,
opioid analgesics, a2 agonists, non-steroidal anti-inflammatory drugs (NSAIDs)
and steroids. Each of these needs to be administered frequently and also has
limitations in efficacy and safety. There is accordingly a need for an infrequently
dosed, long lasting and efficacious form of pain relief for canines suffering from
chronic pain, such as those with cancer pain or arthritis.
While NGF is expressed in canine tissues and the canine NGF le has been
characterised (Eisele l. Wood IS. German AJ. Hunter L. Trayhurn P.” Adipokine
gene expression in dog adipose tissues and dog white adipocytes differentiated in
primary culture” Hormone & Metabolic Research. 37(8):474-81, 2005 Genbank
XP_540250), no antagonist to canine NGF has been bed, nor has the use of
ng NGF mediated signalling in canines to prevent or alleviate pain. The use
in s of known antibodies which act as anti-NGF antagonists in other species
would not be le due to the production of neutralising antibodies.
Furthermore, the production of a chimeric antibody comprising canine derived
constant domains and variable domains derived from a known anti-NGF antibody
such as alphaD11 could not be guaranteed to bind to canine NGF. Furthermore,
such an dy may exhibit cross-reactivity to other target epitopes which may
be present in canines, but not present in the species from which the antibody was
originally derived. Furthermore, the production of neutralising dies would
limit the long term therapeutic administration of the antibody, this being a
particularly important requirement when treating a chronic pain related condition or
a cancerous condition. Likewise, the production of a sed form of an anti-
NGF antibody using CDR grafting, or a related technique may also result in
neutralising dy tion and may further exhibit a reduction in antigen
binding affinity and avidity. Accordingly, there is a serious need for g
s which act as antagonists of canine NGF for use in pain management in
canines, wherein the binding members retain high levels of binding affinity and
avidity, while avoiding the tion of neutralising antibodies there against.
Summary of the invention
Following extensive efforts, the present inventor has surprisingly fied a
method for preparing antibodies which produces non-immunogenic antibodies and
binding fragments which bind ically to canine NGF and which neutralise
canine NGF biological activity. In particular, it is demonstrated herein, quite
unexpectedly, that the binding of the antibodies and binding fragments of the
ion to canine NGF sequesters the ical activity of canine NGF by
inhibiting the binding of canine NGF to the high affinity TrkA receptor or to the p75
receptor. This, in turn, prevents the upregulation of neuropeptides in sensory
neurons with the resulting effect that the sensation of pain will be reduced or
removed. The antibodies have been produced using recombinant DNA methods
and are unexpectedly non-immunogenic, that is, neutralising antibodies are not
raised against them following administration to a canine t. Such a finding is
entirely surprising and unexpected, as the antibodies were not produced using
rd methodologies, such as CDR grafting, or the like.
According to a first aspect of the invention there is ed a method of preparing
an antibody suitable for use in a canine comprising or consisting essentially of the
steps of:
- providing a donor antibody from a s other than a canine, wherein
the donor antibody has binding specificity for a target n present in canines;
- comparing each amino acid residue of the amino acid sequence of
framework regions of the donor dy with each amino acid residue present at
a corresponding position in the amino acid sequence of framework regions of one
or more canine antibodies to identify one or more amino acid residues within the
amino acid sequence of the framework regions of the donor antibody that differ
from one or more amino acid residues at the corresponding position within the
amino acid sequence of framework regions of the one or more canine dies;
- substituting the one or more identified amino acid residues in the donor
antibody with the one or more amino acid residues present at the corresponding
position in the one or more canine antibodies.
The method of the present invention modifies a donor antibody for use in a canine
in such a way that the modified antibody does not contain any amino acid in any
position within the framework regions which would be foreign at that position in
canines. The modified dy therefore retains the specificity and affinity of the
donor antibody for the target antigen, but importantly is modified such that no
potentially foreign epitopes are created. The modified dy is therefore not
seen as foreign in canines and hence does not induce an immune response in
canines which could lead to a neutralisation of the efficacy of the antibody,
especially ing long term administration.
In certain embodiments, the step of substituting the one or more fied amino
acid es ses substituting the one or more identified amino acid
residues with the one or more amino acid residues present at the corresponding
position which have the highest homology to the one or more substituted amino
acid residues.
In certain embodiments, the method further comprises the step of replacing
constant domains of the heavy chain and/or light chain of the donor antibody with
constant domains of a heavy and/or light chain derived from a canine antibody.
Typically, the constant domain of the heavy chain is ed with a type HCA or
HCD canine constant domain.
In certain embodiments, the target antigen is nerve growth factor (NGF).
The method of the first aspect of the invention does not comprise CDR grafting.
Antibodies prepared according to the method of the first aspect of the invention
comprise CDRs of the donor antibody, caninised ork s prepared
ing to the method of the first aspect of the invention and canine constant
domains.
The present invention extends to antibodies prepared according to the first aspect
of the present invention such as those described below.
WO 53121
Accordingly, according to a further aspect of the ion there is provided a
caninised antibody or binding fragment thereof which binds specifically to canine
neuronal growth factor (NGF). Typically, the sed antibody or binding
fragment thereof neutralises NGF biological function, when bound thereto. That is,
the binding of the caninised antibody or binding fragment to NGF sequesters the
ability of NGF to bind to the TrkA receptor or to the p75 receptor. In certain
embodiments, the caninised antibody, or binding fragment f, binds to NGF
with a binding affinity KB of 1X10'8 or less.
In a further or related aspect of the invention there is provided a neutralising
antibody, or an antigen binding fragment thereof, which is capable of specifically
binding to canine nerve growth factor (NGF), the antibody or dy binding
fragment comprising, consisting of or consisting essentially of a light chain variable
region comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or
an amino acid sequence which has an identity of at least 85, 90, 95 or 99%
thereto. In certain embodiments said ty is over a length of at least about 15
amino acids, preferably about 20 amino acids, more preferably about 25 amino
acids.
In some embodiments the neutralising antibody is a monoclonal antibody. In
some embodiments, the antibody is a chimeric antibody. In some embodiments,
the antibody is a caninised antibody, that is, an antibody which has an amino acid
sequence which has been de-immunised such that lising antibodies will not
be produced there against when administered to a canine subject. In certain
embodiments, the caninised dy is ed according to the method of
preparing an antibody of the first aspect of the invention. Typically the heavy
chain constant domains of the antibody are selected or modified by way of amino
acid substitution or deletion such that the constant domains do not mediate
ream or functions.
2012/051002
In some embodiments, the dy or antibody binding fragment comprises,
consists of, or consists essentially of a light chain comprising the amino acid
sequence of SEQ ID NO:5 or SEQ ID NO:10, or an amino acid sequence which
has at least 85, 90, 95 or 99% sequence homology thereto. In certain
embodiments said identity is over a length of at least about 15 amino acids,
preferably about 20 amino acids, more preferably about 25 amino acids.
In a further or related aspect, there is provided a neutralising antibody, or an
antigen g fragment thereof, which is capable of specifically binding to canine
nerve growth factor (NGF), the antibody or antibody g fragment sing,
consisting of or consisting essentially of a heavy chain le region comprising
the amino acid sequence of SEQ ID N02 or SEQ ID NO:4 or an amino acid
ce which has an identity of at least 85, 90, 95 or 99% thereto. In certain
embodiments said identity is over a length of at least about 15 amino acids,
preferably about 20 amino acids, more preferably about 25 amino acids.
lly, the variable region of the heavy chain (VH) is conjoined to a further
amino acid sequence which comprises at least one immunoglobulin constant
domain. In certain embodiments, the immunoglobulin constant domain is derived
from an antibody of the ss IgG (immunoglobulin G) to form the complete
heavy chain of the caninised antibody of the invention. Four different canine
constant domains are known. Typically, said nt domains comprise CH1,
CH2 and CH3 along with a suitable linker (or “hinge”) located between the CH1
and CH2 domains. Typically, the anti-canine NGF antibody of the invention
comprises a heavy chain variable domain ned to a constant domain, wherein
the constant domain does not mediate downstream effector functions such as
complement fixation, ADCC, Fc receptor binding, or the like. Typically said heavy
chain has a canine heavy chain isotype A or D.
In certain embodiments, the antibody or antibody binding fragment comprises,
consists of, or consists essentially of a heavy chain sing the amino acid
sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ
ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 andSEQ
ID NO:14, or an amino acid sequence which has a sequence identity of at least
85, 90, 95 or 99% thereto. In certain embodiments said identity is over a length of
at least about 15 amino acids, preferably about 20 amino acids, more preferably
about 25 amino acids.
In certain further embodiments, the antibody or binding fragment may comprise a
heavy chain where at least one amino acid residue in the constant domain has
been tuted or deleted in order to t the glycosylation of that amino acid
residue. Accordingly, in certain further embodiments, the dy or antibody
binding nt comprises, consists of, or consists essentially of a heavy chain
comprising the amino acid sequence ed from the group consisting of SEQ ID
NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID
NO:20, SEQ ID N021 and SEQ ID NO:22, or an amino acid sequence which has
a sequence identity of at least 85, 90, 95 or 99% thereto. In n embodiments
said identity is over a length of at least about 15 amino acids, preferably about 20
amino acids, more preferably about 25 amino acids.
In some embodiments, antibodies or fragments having a heavy chain constant
domain which do not mediate downstream effector functions such as ment
fixation, ADCC, Fc receptor binding, or the like are preferred. Such heavy chains
may comprise heavy chains of the canine derived subtype lgG-A and may have an
amino acid sequence of SEQ ID NO:6, 11, 15 or 19. Further, such heavy chains
may comprise heavy chains of the canine derived subtype lgG-D and may have an
amino acid sequence ofSEQ ID NO:9, 14, 18 and 22.
In a further or related aspect, the present invention extends to a neutralising
antibody, or an antigen binding fragment thereof, which is e of specifically
binding to canine nerve growth factor (NGF), the antibody or antibody binding
fragment comprising, ting of or consisting essentially of a light chain and a
heavy chain wherein the variable region of the light chain (VL) comprises an amino
acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or an amino acid sequence which
has a sequence identity of at least 85, 90, 95 or 99% thereto, and wherein the
variable region of the heavy chain (VH) comprises, consists or consists essentially
of an amino acid sequence which is identical or substantially homologous to the
amino acid sequence of SEQ ID N02 or SEQ ID NO:4 or an amino acid sequence
which has a sequence identity of at least 85, 90, 95 or 98% thereto. In certain
embodiments said identity is over a length of at least about 15 amino acids,
preferably about 20 amino acids, more ably about 25 amino acids.
In certain ments, the antibody or binding member comprises a light chain
which comprises, consists of or consists essentially of the amino acid sequence of
SEQ ID NO:5 or SEQ ID NO:10, or to a sequence having an amino acid identity of
at least 85%, more preferably of 95% and most preferably at least 98% identity
thereto. In certain embodiments said identity is over a length of at least about 15
amino acids, preferably about 20 amino acids, more preferably about 25 amino
acids.
In certain embodiments, the antibody or binding member comprises a heavy chain
which comprises, consists of or consists essentially of an amino acid sequence
selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8,
SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14,
or an amino acid ce having a sequence identity of at least 85%, more
preferably of 95% and most preferably at least 98% thereto. In certain
embodiments said identity is over a length of at least about 15 amino acids,
preferably about 20 amino acids, more preferably about 25 amino acids.
In certain ments, the antibody may be conjugated to at least one er
molecule.
In certain r embodiments at least one residue in the constant domain can be
substituted or deleted in order to prevent the ylation of that residue.
Accordingly, in certain further embodiments, the antibody or antibody binding
nt comprises, ts of, or consists essentially of a heavy chain
sing the amino acid sequence selected from the group consisting of SEQ ID
NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID
NO:20, SEQ ID NO:21 and SEQ ID NO:22, or a sequence having an amino acid
identity of at least 85%, more preferably of 95% and most preferably at least 98%
identity o. In certain embodiments said identity is over a length of at least
about 15 amino acids, preferably about 20 amino acids, more ably about 25
amino acids.
The inventor has further defined a series of framework regions (FR) which can be
combined with complementarity determining regions (CDRs) to form caninised
heavy and light chain variable domains. Each of the heavy and light chain
domains has 4 framework regions, designated FR1, FR2, FR3 and FR4.
An antibody molecule may comprise a heavy chain variable domain comprising
CDR1, CDR2 and CDR3 regions and associated interposed ork regions.
The heavy chain variable domain (VH) CDRs are known as HCDRs, with these
CDRs being found at the ing positions according to the Kabat numbering
system: VHCDR1 — Kabat residues 31-35, VHCDR2 — Kabat residues 50-65,
VHCDR3 — Kabat residues 95-102 (Kabat EA et al. (1991) Sequences of proteins
of immunological interest, 5th edition. da: US Department of Health and
Human Services).
Furthermore, an dy further comprises a light chain variable domain
comprising CDR1, CDR2 and CDR3 regions and associated interposed framework
regions. The light chain variable domain (VL) CDRs are known as VLCDRs, with
these CDRs being found at the following amino acid e positions according to
the Kabat numbering system: VLCDR1 — Kabat residues 24-34, VLCDR2 — Kabat
residues 50-56, VLCDR3 — Kabat residues 89-97.
A light or heavy chain variable domain comprises four framework regions, FR1,
FR2, FR3 and FR4, interposed with CDRs in the following arrangement: FR1-
CDR1-FR2—CDR2—FR3-CDR3-FR4.
In a yet further aspect, the present invention s to an anti-NGF antibody, or
an NGF binding fragment thereof, the antibody or antibody binding fragment
comprising a light chain variable region comprising at least one of:
an FR1 framework region consisting or comprising of the amino acid
sequence of SEQ ID NO:23 or SEQ ID NO:24,
an FR2 framework region consisting or comprising of the amino acid
sequence ofSEQ ID NO:25,
an FR3 framework region consisting or comprising of the amino acid
sequence of SEQ ID NO:26 or SEQ ID NO:27,
an FR4 framework region consisting or comprising of the amino acid
ce ofSEQ ID NO:28,
and/or a heavy chain variable region comprising at least one of:
an FR1 framework region consisting or comprising of the amino acid
sequence ofSEQ ID NO:29,
an FR2 framework region consisting or comprising of the amino acid
sequence ofSEQ ID NO:30,
an FR3 framework region consisting or comprising of the amino acid
sequence ofSEQ ID NO:31 or SEQ ID NO:32,
an FR4 framework region ting or comprising of the amino acid
sequence ofSEQ ID NO:33.
Typically the light and heavy chain CDRs are derived from an antibody which has
binding specificity to canine NGF.
Typically, the production of the caninised anti-canine NGF antibody of the
invention does not e back mutations to be introduced into the framework
regions of the light or heavy chain le domains.
In certain embodiments, the light chain variable domain comprising said at least
one ork region described above is conjoined to a canine derived light chain
constant domain, typically a light chain kappa constant domain, but optionally a
lambda light chain. In certain embodiments, said light chain comprises an FR1
region with an amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24, an FR2
region with an amino acid sequence of SEQ ID NO:25, an FR3 region with an
amino acid sequence ofSEQ ID NO:26 or SEQ ID N027, and an FR4 region with
an amino acid sequence of SEQ ID NO:28 or a framework region with an amino
acid sequence which has a sequence identity of at least 85, 90, 95 or 98% to the
foregoing. In certain embodiments said identity is over a length of at least about 5
amino acids, preferably about 10 amino acids.
In certain further embodiments, the heavy chain variable region comprising at least
one of the framework s described above is conjoined to a canine derived
heavy chain constant . In certain embodiments, the amino acid sequence
of the constant domain lacks any post-translational modifications, or may be
modified to remove any or all residues which may be t to N-linked or O-
linked ylation, such that the constant domains are aglycosylated. In n
embodiments the heavy chain comprises an FR1 region with an amino acid
sequence ofSEQ ID NO:29, an FR2 region with an amino acid sequence of SEQ
ID NO:30, an FR3 region with an amino acid sequence ofSEQ ID NO:31 or SEQ
ID NO:32 and an FR4 region with an amino acid sequence of SEQ ID NO:33 or a
framework region with an amino acid sequence which has a sequence identity of
at least 85, 90, 95 or 98% to the foregoing. In certain embodiments said identity is
over a length of at least about 5 amino acids, preferably about 10 amino acids.
In n r embodiments, modifications may be made to the framework
regions described herein. That is, the inventor has identified that for some
residues in each ork region, there is a choice of amino acid residues which
may be present at a given position. Importantly, these framework region
modifications do not result in a conformational change to the complementarity
determining regions, as this may alter the binding specificity and/or affinity of the
resulting antibody. In certain embodiments, the invention extends to introducing 2
or more amino acid tutions to the amino acid residues of the framework
regions of the light chain variable region and/or heavy chain variable region.
Accordingly, in certain further embodiments, the invention extends to polypeptides,
such as an antibody, or antigen binding nt thereof, which comprises a light
chain variable domain having an FR1 region comprising the amino acid sequence
of SEQ ID NO:23 which has been modified by one or more of the following amino
acid substitutions (where the amino acids are denoted by their single letter code):
amino acid residue Q at position 3 (Q3) is replaced by the amino acid residue V,
T5 is M, S7 is T, A9 is L, L13 is V, Q15 is P or R, E16 is G, K18 is Tor P, V19 is A,
T20 is S, and T22 is S. Furthermore, one or more of the following substitutions
may be further be provided: T5 is l, A9 is P, S12 is A, S14 is R or T, E16 is D, E17
is D, K18 is A, E or L, T22 is Y and C23 is Y.
In n further ments, where the light chain variable domain has the FR1
region comprising the amino acid sequence of SEQ ID NO:24, this may be
modified by one or more of the following amino acid substitutions: amino acid
residue V at position 3 (V3) is ed by the amino acid residue Q, T5 is M, S7 is
T, A9 is L, L13 is V, Q15 is P or R, E16 is G, K18 is Tor P, V19 is A, T20 is S, and
T22 is S. Furthermore, one or more of the ing substitutions may be further
be provided: T5 is l, A9 is P, S12 is A, S14 is R or T, E16 is D, E17 is D, K18 is A,
E or L, T22 is Y and C23 is Y.
In certain further embodiments, the light chain FR2 region having the amino acid
sequence of SEQ ID NO:25 may be ed by one or more of the following
amino acid substitutions: Y2 is F, Q3 is R, A9 is S, K11 is Q, and L12 is R.
Furthermore, Y2 can be I or L, Q3 can be I or L, Q4 can be H, K5 can be R, P6
can be A or S, G7 can be D, A9 can be P or T, K11 can be E or R, L12 can be A,
G, P or S, I14 can be L, and Y15 can be E, F, N, S orV.
In certain further embodiments, the light chain FR3 region having the amino acid
sequence of SEQ ID NO:26 may be modified by one or more of the following
amino acid substitutions: S4 is D, E14 is D, Y15 is F, S16 is T, L17 is F, T18 is K,
N20 is S, L22 is V, S24 is P, V27 is A, F31 is Y. Furthermore, G1 can be A, V2
2012/051002
can be A, P3 can be S, F6 can be L or V, S7 can be I, G8 can be A, T13 can be A,
S16 can be R, T18 can be R, S24 can be A, E25 can be D, G, l or N, V27 can be
G, S or T, A28 can be G, and V29 can be I or L.
In certain further embodiments, where the light chain variable domain has the FR3
region comprising the amino acid sequence of SEQ ID NO:27, this may be
modified by one or more of the following amino acid substitutions: S4 is D, E14 is
D, F15 is Y, S16 is T, L17 is F, T18 is K, S20 is N, L22 is V, P24 is S, V27 is A,
Y31 is F. Furthermore, G1 can be A, V2 can be A, P3 can be S, F6 can be L or V,
S7 can be I, G8 can be A, T13 can be A, S16 can be R, T18 can be R, S24 can be
A, E25 can be D, G, l or N, V27 can be G, S or T, A28 can be G, and V29 can be I
or L.
In certain further embodiments, the light chain FR4 region having the amino acid
sequence of SEQ ID NO:28 may be modified by one or more of the following
amino acid substitutions: E8 is D. Furthermore, G2 can be S, A3 can be P, Q or T,
G4 can be E, T5 can be P, K6 can be Q or S, V7 can be L or W, E8 can be R, or
L9 can be I.
In certain further embodiments, the heavy chain FR1 region having the amino acid
sequence of SEQ ID NO:29 may be modified by one or more of the following
amino acid tutions: D10 is G, N13 is Q, G15 is T, G16 is E, T17 is S, T19 is
R, V24 is A, S28 is T, L29 is F, T30 is S. Furthermore, E1 can be D or G, V2 can
be E, G,|, L or M, Q3 can be A, E, H, K, L, P, R, S or V, L4 can be P or V, V5 can
be A, E, L or M, E6 can be A or Q, S7 can be F, L or T, G9 can be E, D10 can be
A, E, N or T, L11 can be Q, R, VorW, V12 can be A, l or M, N13 can be Kor R,
P14 can be F or T, G15 can be Aor E, G16 can be A, T17 can be P, L18 can be
R, T19 can be G, K or V, L20 can be I or V, S21 can be Y, V23 can be A, E, l or L,
V24 can be G, l, S or T, S25 can be G, P or T, G26 can be D, R or T, F27 can be
D, l, L, S, T or V, S28 can be A, D, l, L, M, N, P or R, L29 can be I, M or V, T30
can be D, G, H, l, K, N, R, V.
In certain further embodiments, the heavy chain FR2 region having the amino acid
sequence of SEQ ID NO:30 may be ed by one or more of the following
amino acid substitutions: L6 is P, R8 is K, E11 is Q, G14 is A. Furthermore, W1
can be C, V2 can be A, F, l or L, Q4 can be H or L, A5 can be D, G, P, S, T or V,
G7 can be E, L or R, R8 can be A, E, G, M or Q, G9 can be D, E, R, T or V, L10
can be F, M or P, E11 can be D, H, L, P or R, W12 can be C, F, L, M, S orY, V13
can be F, l or L, G14 can be L,S or T.
In certain further embodiments, the heavy chain FR3 region having the amino acid
sequence of SEQ ID NO:31 may be modified by one or more of the following
amino acid substitutions: L2 is F, T5 is S, T8 is N, S9 is A, S11 is N, V13 is L, F14
is Y, K16 is Q, H18 is N, Q21 is R, S22 is A, T27 is V, R32 is K. Furthermore, R1
can be Q, L2 can be V, T3 can be A, l or S, l4 can be L, M, T or V, T5 can be A or
F, R6 can be K, D7 can be E or N, T8 can be D, G, l or S, S9 can be D, G, P, T or
V, K10 can be E, G, M, N, Q or R, S11 can be D, H, Kor R, T12 can be A, l, M or
S, V13 can be A, | or M, F14 can be H, S orT, L15 can be I, K16 can be A, D, E, H
or R, M17 can be L, H18 can be D, K, P, R, S or T, S19 can be D, G, N, RorT,
L20 can be V, Q21 can be G, l, K, S or T, 822 can be D, G, P, T or V, E23 can be
A, D or V, T25 can be A, M or S, A26 can be G or V, T27 can be F, l, K, L, M or Q,
Y28 can be H, Y29 can be F or H, A31 can be C, G, L, M, R, S, T or V, R32 is A,
D, E, G, l, L, M, N, P, Q, S, TorV.
In certain further embodiments, where the heavy chain variable domain has the
FR3 region comprising the amino acid ce of SEQ ID NO:32, this may be
modified by one or more of the following amino acid substitutions: L2 is F, T5 is S,
T8 is N, S9 is A, S11 is N, V13 is L, F14 is Y, Q16 is K, H18 is N, R21 is Q, S22 is
A, T27 is V, R32 is K. Furthermore, R1 can be Q, L2 can be V, T3 can be A, l or
S, l4 can be L, M, T or V, T5 can be A or F, R6 can be K, D7 can be E or N, T8
can be D, G, l or S, S9 can be D, G, P, TorV, K10 can be E, G, M, N, Q or R, S11
can be D, H, Kor R, T12 can be A, l, M or S, V13 can be A, l or M, F14 can be H,
S or T, L15 can be I, K16 can be A, D, E, H or R, M17 can be L, H18 can be D, K,
P, R, S or T, S19 can be D, G, N, R or T, L20 can be V, Q21 can be G, l, K, S or
T, S22 can be D, G, P, T or V, E23 can be A, D or V, T25 can be A, M or S, A26
can be G or V, T27 can be F, l, K, L, M or Q, Y28 can be H, Y29 can be F or H,
A31 can be C, G, L, M, R, S, T or V, R32 is A, D, E, G, l, L, M, N, P, Q, S, Tor V.
In certain further embodiments, the heavy chain FR4 region having the amino acid
sequence of SEQ ID NO:33 may be modified by one or more of the following
amino acid substitutions: L6 is S. Furthermore, W1 can be L, G2 can be A or S,
Q3 can be D, H, P or R, T5 can be A, l, N or S, L6 can be P, Q or R, V7 can be I, L
or P, T8 can be A, F, l, L, P, S or Y, V9 can be A, S10 can be A, C, P or T, S11
can be A, L or P.
In certain ments of the above aspects of the invention, the antibody is a
monoclonal antibody. Typically the antibody is a caninised antibody.
In certain ments of the above aspects of the invention, the caninised NGF
neutralising antibody of the invention, or the binding fragment derived therefrom
ically binds to canine NGF (nerve growth factor) with a binding affinity having
an equilibrium dissociation constant (KB) of 1x10'8 or less. Furthermore, it is
preferred that the caninised antibodies are not cross-reactive to any other epitopes
present in canines, and r that neutralising antibodies are not ted
against the antibodies of the invention when they are administered to a canine.
Furthermore, it is preferred that the nt domains of the antibodies do not
mediate any downstream effector functions including, but not limited to,
complement fixation and activation, ADCC and Fc receptor binding and activation.
In certain embodiments of the above aspects of the invention, the antibody, or
antigen binding fragment thereof, has a serum half-life in canines of at least one
week. lly, the serum half-life is at least 8 days. Typically, the antibody is
not immunogenic in canines.
In certain embodiments of the above aspects of the invention, the antibody, or
n binding nt thereof, is purifiable or purified by a method comprising
anion exchange chromatography, hydrophobic ction chromatography and
size exclusion chromatography. ln alternative embodiments, the dy, or
n binding fragment thereof, is purifiable or purified by a method comprising
Captoadhere affinity chromatography followed by anion exchange
chromatography.
In certain embodiments, the antibody, or antigen binding fragment thereof, does
not mediate downstream effector functions. Typically the antibody or binding
fragment has a canine heavy chain isotype A or D.
In certain ments, the caninised antibody is prepared according to the
method of ing an antibody of the first aspect of the invention.
In certain further embodiments, modifications to the amino acid sequence of the
constant regions of the heavy chain may be made to the antibodies of the
invention. Said modification may involve the addition, substitution or on of
one or more amino acid residues. Said amino acid changes are typically
performed in order to modify the functional characteristics of the antibody. For
example, amino acid cation may be performed to prevent downstream
effector functions mediated by the antibody constant domains, for e by
preventing the ability of the antibody to bind to Fc receptors, activate complement
or induce ADCC. Furthermore, modifications may be made to the amino acid
es of the hinge region of the heavy chain constant domain in order to modify
the circulatory half life of an antibody when it is administered to a canine.
The present invention extends to antibody fragments which bind to canine NGF
and ter its ability to bind to the p75 or TrkA receptors.
In certain embodiments the antibody binding fragment may comprise a heavy
chain and light chain sequence of the invention being connected by a le
linker to form a single chain antibody.
A single chain Fv (scFv) comprises a VH and VL domain. The VH and VL
domains associate to form a target binding site. These 2 domains are covalently
linked by a peptide linker. A scFv molecule can have the form of VL-linker-VH, in
cases where the light chain variable domain is required at the N-terminal, or as
VH-linker—VL in cases where the VH domain is required at the N-terminal.
Accordingly, in certain further embodiments, the antigen binding fragment is a
single chain Fv (scFv) antibody fragment. In certain further embodiments, the
antibody binding fragment is selected from the group consisting of, but not limited
to, a Fab antibody fragment, a Fab’ dy fragment, a F(ab’)2 antibody
fragment, an Fv antibody fragment, a scFV antibody fragment, and the like.
In some embodiments, the invention provides multispecific or multivalent
antibodies comprising an anti-NGF antibody or binding fragment of the invention
coupled or conjoined to other antibodies with ent binding icities for use
in combination therapy. A multispecific antibody comprises at least one antibody
or binding fragment specific to a first NGF epitope, and at least one binding site
specific to another epitope present on NGF, or to a ent antigen. A multivalent
antibody comprises antibodies or antibody binding fragments which have binding
specificity to the same NGF e. ingly, in certain embodiments, the
invention extends to an antibody fusion protein comprising four or more Fv regions
or Fab regions of the caninised antibodies of the present invention. A yet further
embodiment extends to an antibody fusion protein comprising one or more Fab
region d from an dy described herein along with one or more Fab or
Fv regions from antibodies specific for NGF. In certain further embodiments, the
invention extends to a bispecific antibody, wherein an antibody or g fragment
thereof according to the present invention is linked to a ary antibody or
binding fragment thereof which has binding ic for a ary target, said
target not being NGF. Preferably said secondary target s in preventing NGF
ed signalling through the p75 or TrkA receptors. Such multivalent,
bispecific or multispecific antibodies can be made by a variety or recombinant
methods which would be well known to the person skilled in the art.
A yet further aspect of the invention provides an anti-neurotrophin neutralising
antibody comprising a light chain variable domain having the amino acid sequence
of SEQ ID NO:1 or SEQ ID NO:3 and/or a heavy chain le domain having the
amino acid sequence ofSEQ ID N02 or SEQ ID NO:4. In certain embodiments,
the neurotrophin is canine nerve growth factor (NGF).
A yet further aspect of the invention es a method for treating, inhibiting or
ameliorating pain in a canine, the method comprising the steps of:
- providing a therapeutically effective amount of an anti-canine NGF
antibody, or antigen binding fragment f, and
- administering the same to a canine in need thereof.
In n embodiments, the antibody is a caninised antibody.
In certain embodiments, the antibody ses a light chain variable domain
comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or a
ce which has at least 85% identity thereto and/or a heavy chain variable
domain comprising the amino acid sequence of SEQ ID N02 or SEQ ID NO:4 or
an amino acid ce having at least 85% sequence gy thereto.
In certain embodiments, the antibody comprises a light chain having the amino
acid sequence of SEQ ID NO:5 or SEQ ID NO:10 or a sequence having a
sequence identity of at least 85% thereto and/or a heavy chain which ses,
consists of or consists essentially of an amino acid sequence selected from the
group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,
SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or a sequence
having an amino acid identity of at least 85% and more preferably at least 98%
identity thereto.
In certain embodiments, the anti-canine NGF antibody or antigen binding fragment
thereof is any of those provided by the foregoing aspects of the invention.
In certain ments, the pain is neuropathic pain. In particular, the pain may
be peri-operative, post-operative or post-surgical pain. Post-operative pain may
result following any ing procedure which in s may include, but is not
limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy
ures, castration procedures and the like. In certain further embodiments,
the pain is chronic pain associated with cancer or a cancerous condition
(oncologic pain). In certain further embodiments, the pain is associated with, or
resulting from, rheumatoid arthritis or osteoarthritis. In certain embodiments, the
pain is inflammatory pain or pruritic pain.
According to a yet further aspect of the present invention there is provided a
method for the treatment of arthritis or an arthritic condition in a canine subject,
said method comprising the steps of:
- providing a therapeutically effective amount of an anti-canine NGF
antibody according to the ion or antigen binding fragment f, and
- administering the same to a canine in need thereof.
In certain embodiments, the antibody is a caninised dy. In certain
embodiments, the antibody comprises a light chain variable domain comprising the
amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or a sequence which has
at least 85% identity thereto and/or a heavy chain le domain comprising the
amino acid sequence of SEQ ID N02 or SEQ ID NO:4 or an amino acid sequence
having at least 85% sequence homology thereto.
In certain embodiments, arthritis or tic condition es the conditions
selected from the group consisting of immune mediated polyarthritis, rheumatoid
arthritis, osteoarthritis and related conditions.
lly, the ent of the arthritis or arthritic condition comprises ameliorating,
inhibiting, reducing, suppressing or delaying the onset of pain associated with, or
attributable to, the arthritic condition.
A r aspect of the present invention provides a method for the ent of a
condition caused by, associated with or resulting in increased expression of canine
NGF or increased sensitivity to NGF in a canine subject, said method comprising
the steps of:
- providing a therapeutically effective amount of a caninised anti-canine
NGF antibody according to the invention or antigen binding fragment
thereof, and
- administering the same to a canine in need thereof.
ing to a yet further aspect of the present invention there is provided a
method for the treatment of a tumour induced to proliferate by NGF in a canine
and conditions associated therewith, said method comprising the steps of:
- providing a therapeutically effective amount of an anti-canine NGF
antibody ing to the invention or antigen binding fragment thereof, and
- administering the same to a canine in need thereof.
In certain embodiments, the tumour is an osteosarcoma. In certain embodiments,
the tumour is induced to proliferate by autocrine or paracrine NGF.
In n embodiments, the ing s of the invention further comprise
the step of co-administering at least one further agent which may enhance and/or
complement the iveness of the anti-NGF antibody of the invention. For
example, the antibody or antigen binding fragment thereof may be co-administered
along with at least one analgesic, NSAID, opioid, corticosteroid or steroid.
Examples of suitable analgesics include, but are not d to, butorphanol,
buprenorphine, fentanyl, flunixin meglumine, merpidine, morphine, nalbuphine and
derivatives f. Suitable NSAIDS include, but are not limited to,
acetaminophen, acetylsalicylic acid, carprofen, etodolac, ketoprofen, meloxicam,
firocoxib, coxib, deracoxib and the like.
2012/051002
In certain further embodiments, the at least one further agent may be a
therapeutically active agent which may be one or more of the group selected from
an antibiotic, an antifungal therapeutic agent, an antiprotozoal therapeutic agent,
an antiviral therapeutic agent or similar therapeutic agents. Furthermore the at
least one further agent may be an inhibitor of or(s) of inflammation such as
a PGE-receptor antagonist, an immunosuppressive agent, such as cyclosporine,
or an anti-inflammatory glucocorticoids. In certain further embodiments the at
least one further agent may be an agent which is used for the ent of
cognitive dysfunction or impairment, such as memory loss or related conditions
which may become increasingly ent in older canines. Further still, the at
least one further agent may be an anti-hypertensive or other compound used for
the treatment of cardiovascular ction, for example, to treat hypertension,
myocardial ischemia, congestive heart failure and the like. Further still, the at least
one further agent may be a diuretic, vasodilator, beta-adrenergic receptor
antagonist, angiotensin-ll converting enzyme inhibitor, calcium channel blocker or
HMG-CoA reductase tor.
In certain embodiments, the dy or antigen binding fragment is administered
to the canine as part of the foregoing methods at a dose g from about 0.01
mg/kg of body weight to about 10 mg/kg of body , in particular from 0.03
mg/kg of body weight to about 3 mg/kg of body weight.
In various further aspects, the t invention extends to a composition
sing an antibody or binding fragment thereof according to any foregoing
aspect of the invention. In certain embodiments, the composition further
comprises at least one pharmaceutically acceptable carrier.
A yet further aspect of the invention provides a pharmaceutical composition for
treating pain or a condition resulting in or caused by chronic pain in a canine or a
tumour d to proliferate by NGF, comprising a pharmaceutically effective
amount of an antibody according to the present invention, along with at least one
pharmaceutically acceptable r, excipient or diluent.
In certain embodiments, the composition may further comprise at least one
analgesic, NSAID, opioid, corticosteroid or steroid.
In various further aspects, the present invention extends to an isolated nucleic acid
which encodes the antibody or antibody binding fragments of the invention.
Accordingly, a yet further aspect of the invention provides an isolated nucleic acid
that encodes an antibody or antigen binding fragment according to any of the
foregoing aspects of the invention.
In certain embodiments, the polynucleotide encodes a light chain variable domain
of an anine NGF antibody or dy fragment having the amino acid
sequence of SEQ ID NO:1 or SEQ ID NO:3, or a light chain having the amino acid
sequence of SEQ ID NO:5 or 10.
In certain further embodiments the polynucleotide s a heavy chain variable
domain of an anti-canine NGF antibody or antibody fragment having the amino
acid sequence of SEQ ID N02 or SEQ ID NO:4 or a heavy chain having the
amino acid sequence selected from the group consisting of SEQ ID NO:6— SEQ ID
NO:9, SEQ ID NO:11- SEQ ID NO:14, SEQ ID NO:15- SEQ ID NO:18 and SEQ ID
NO:19- SEQ ID NO:22.
In certain embodiments, the isolated c acid further encodes one or more
regulatory ces operably linked thereto.
In a r aspect there is provided an expression vector comprising a
polynucleotide comprising a polynucleotide encoding a heavy and/or light chain
variable domain or a heavy and/or light chain constant domain of the invention. In
certain embodiments the sion vector further comprises one or more
regulatory ces. In n embodiments the vector is a plasmid or a
retroviral vector.
2012/051002
A yet further aspect es a host cell incorporating the sion vector of the
foregoing aspect of the invention. A further aspect of the invention provides a host
cell which produces the antibody of any of the foregoing aspects of the invention.
A yet further aspect of the ion provides a method for producing an anti-
canine NGF neutralising antibody, the method comprising the step of culturing the
host cell of the foregoing aspect of the invention to allow the cell to express the
anti-canine NGF neutralising antibody.
A further aspect of the t invention provides a method of purifying an anti-
canine NGF dy according to the invention comprising the steps of:
- (i) anion exchange chromatography;
- (ii) hydrophobic ction chromatography; and
- (iii) size exclusion chromatography.
A further aspect of the present invention provides a method of purifying an anti-
canine NGF antibody according to the invention comprising the steps of:
- (i) Captoadhere affinity chromatography; and
- (ii) anion exchange chromatography.
A yet further aspect of the present invention provides a method of producing an
anti-canine NGF caninised antibody according to the invention comprising the
steps of expressing one or more of the polynucleotides / nucleic acids or vectors of
the foregoing aspects of the invention which express the light and/or heavy chains
of the antibodies of the invention in a suitable host cell, recovering the expressed
polypeptides, which may be expressed er in a host cell, or separately in
ent host cells, and isolating antibodies.
A yet further aspect of the invention provides a method for ng, ameliorating or
inhibiting pain in a canine or treating a tumour induced to proliferate by NGF, the
method comprising the step of stering to the canine an effective amount of a
polynucleotide according to any of the foregoing aspects of the ion.
A yet further aspect of the invention provides an antibody or antibody binding
fragment according to any of the foregoing aspects of the invention, or a
pharmaceutical composition according to the foregoing aspects of the ion, or
a nucleic acid or vector comprising the same according to any of the foregoing
aspects of the invention for use in the treatment or prevention of pain in a canine.
In certain embodiments the pain is acute pain. In certain further embodiments, the
pain is chronic pain. Furthermore, the pain may be post-operative pain, or pain
resulting from any operating procedure which in canines may include, but is not
limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy
procedures, castration procedures and the like. In certain further embodiments,
the pain is chronic pain associated with cancer or a cancerous condition. In
certain further ments, the pain is associated with, or resulting from,
rheumatoid arthritis or rthritis. In certain embodiments, the pain is
inflammatory pain or pruritic pain.
A yet further aspect of the invention provides an antibody or antibody binding
fragment according to any of the foregoing aspects of the invention, or a
pharmaceutical composition according to the foregoing aspects of the invention, or
a c acid or vector comprising the same according to any of the foregoing
aspects of the invention for use in the treatment of arthritis, in particular
osteoarthritis and/or rheumatoid arthritis.
A yet further aspect of the invention provides an antibody or antibody binding
fragment according to any of the foregoing s of the ion, or a
pharmaceutical composition according to the foregoing aspects of the invention, or
a nucleic acid or vector comprising the same according to any of the foregoing
aspects of the invention for use in the treatment of a tumour d to proliferate
by NGF in a canine t and ions ated ith, in particular
osteosarcoma. In certain embodiments, the tumour is induced to proliferate by
ine or paracrine NGF.
A yet further aspect of the invention provides use of an antibody or antibody
binding fragment according to any of the foregoing aspects of the invention, or a
pharmaceutical composition according to the foregoing aspects of the invention, or
a nucleic acid or vector comprising the same according to any of the foregoing
aspects of the invention in the preparation of a ment for the treatment or
prevention of pain in a .
Typically the pain is c pain. rmore, the pain may be post-operative
pain, or pain resulting from any operating procedure which in canines may include,
but is not limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy
procedures, castration procedures and the like. In certain further embodiments,
the pain is chronic pain associated with cancer or a cancerous condition. In
certain further embodiments, the pain is associated with, or resulting from,
rheumatoid arthritis or osteoarthritis. In certain embodiments, the pain is
inflammatory pain or pruritic pain.
A yet further aspect of the invention provides use of an antibody or antibody
binding fragment according to any of the foregoing aspects of the invention, or a
pharmaceutical composition according to the foregoing s of the invention, or
a nucleic acid or vector comprising the same ing to any of the foregoing
aspects of the invention in the preparation of a ment for the treatment,
inhibition amelioration or prevention of rheumatoid arthritis or osteoarthritis in a
canine.
A yet further aspect of the invention provides use of an antibody or dy
binding fragment according to any of the ing aspects of the invention, or a
pharmaceutical composition ing to the foregoing aspects of the invention, or
a nucleic acid or vector comprising the same according to any of the foregoing
aspects of the invention in the preparation of a medicament for the treatment of a
tumour induced to proliferate by NGF in a canine and conditions associated
ith, in particular osteosarcoma. In certain ments, the tumour is
induced to proliferate by autocrine or paracrine NGF.
In a yet r aspect there is provided a cell line, or a tive or progeny cell
thereof that produces anti-canine NGF neutralising monoclonal antibodies, or
fragments f according to the invention.
A yet further aspect of the present invention provides a kit for the treatment of pain
in canines, or for the treatment of a condition associated with pain, or for the
treatment, amelioration or inhibition of pain associated with osteoarthritis or
rheumatoid arthritis comprising an anti-canine NGF antibody of binding fragment
according to any of the foregoing aspects of the invention and instructions for use
of the same.
A yet further aspect of the present invention provides a diagnostic kit for the
detection of an anti-canine NGF monoclonal antibody in fluids in vitro, ex vivo and
in vivo, for use in determining the concentration of said antibody. The kit may
se any of the antibodies of the ion or a binding fragment thereof. The
kit may comprise instructions for use of same.
Brief Description of the Figures
Figure 1 is a graph showing the binding of caninised antibodies produced
according to the invention to murine NGF and canine NGF.
Figure 2A-D shows a series of gels showing protein A purification of the caninised
dies of the invention.
Figure 3 shows a gel showing the results of purification of caninised dies
using SDS—Page.
Figure 4 shows a graph showing the inhibition of NGF induced proliferation of TF-1
cells by caninised antibodies.
Figure 5 shows a graph showing complement deposition induced by antigen-
captured caninised antibodies.
Figure 6 shows the amino acid sequence of a light chain variable domain of the
caninised anti-NGF (SEQ ID NO:1). The three CDR regions, identified according
to Kabat numbering, are underlined. sks above a specific residue indicate
differences in the ce between the caninised sequence and the amino acid
sequence of the rat alphaD11 urine NGF monoclonal antibody.
Figure 7 shows the amino acid sequence of a heavy chain variable domain of the
sed anti-NGF (SEQ ID N02). The three CDR regions, identified according
to Kabat numbering, are underlined. Asterisks above a ic residue te
differences in the sequence between the rat aD11 anti-murine NGF monoclonal
anflbody.
Figure 8 shows the amino acid sequence (SEQ ID NO:5) of a caninised anti-NGF
light chain variable domain canine kappa light chain (caN-kLC) antibody. Variable
domain residues are shown in bold.
Figure 9 shows the amino acid ce (SEQ ID NO:6) of a caninised anti-NGF
heavy chain variable domain canine IgG-A heavy chain CA). Variable
domain residues are shown in bold.
Figure 10 shows the amino acid sequence (SEQ ID NO:7) of a caninised anti-NGF
heavy chain variable domain canine IgG-B heavy chain (caN-HCB). Variable
domain residues are shown in bold.
Figure 11 shows the amino acid sequence (SEQ ID NO:8) of a sed anti-NGF
heavy chain variable domain canine IgG-C heavy chain (caN-HCC). Variable
domain residues shown in bold.
Figure 12 shows the amino acid sequence (SEQ ID NO:9) ofa caninised anti-NGF
heavy chain le domain canine IgG-D heavy chain (caN-HCD). Variable
domain residues are shown in bold.
Figure 13A shows a graph showing the comparison of binding to NGF of anti-
canine-NGF monoclonal antibodies using varying dilutions of SEQ ID No: 5 and 7
and SEQ ID No: 10 and 11. Figure 138 shows a graph showing ment
deposition of the atants from Fig 13A.
Figure 14A shows a graph showing the comparison of binding to NGF of N-
glycosylated and sylated variants of anti-canine-NGF monoclonal antibodies
with H08 and HCC heavy chain isotypes. Figure 148 shows a graph showing
complement deposition of the supernatants from Fig 14A.
Figure 15A and B show the quantitative cation of the anti-canine NGF
antibodies of the present invention using a three-step method (Method I)
comprising (1) anion exchange tography, (2) hydrophobic interaction
chromatography and (3) size exclusion chromatography. Figure 15A shows the
results of fractionation by size exclusion HPLC. Figure 158 shows a reducing
SDS-PAGE gel of fractions following each step. Figure 150 and D show the
quantitative cation of the anti-canine NGF antibodies of the present invention
using a two-step method (Method II) comprising Captoadhere chromatography
and anion exchange chromatography. Figure 150: SDS-PAGE analysis under
non-reducing and reducing conditions. Lane 1 is MWS, lane 2 is 3450 sample 2
ug/mL and 0 ul reducing agent, lane 3 is 3450 sample 4 ug/mL and 0 ul reducing
agent, lane 4 is 3450 sample 6 ug/mL and 0 ul reducing agent, lane 5 is MWS,
lane 6 is 3450 sample 2 ug/mL and 3 ul reducing agent, lane 7 is 3450 sample 4
2012/051002
ug/mL and 3 ul reducing agent, lane 8 is 3450 sample 6 ug/mL and 3 ul reducing
agent and lane 9 is MWS. Figure 15D: size exclusion chromatography.
Figure 16 shows a comparison of anti-NGF monoclonal antibody purified by
Methods l and II. Figure 16A: comparison by non-reducing and reducing SDS—
PAGE. Figure 168: comparison by anti-NGF ELISA.
Figure 17 shows body weight (upper panel) and temperature (lower panel) are
stable following intravenous administration of anine NGF antibodies into
dogs.
Figure 18 shows kinetic analysis of plasma anti-canine NGF monoclonal antibody
concentration following intravenous injection to a dog. A beagle dog was injected
intravenously with GF antibody at 2 mg/kg, s of plasma were taken at
the times indicated and anti-NGF monoclonal antibody was detected by NGF
ELISA. The anine NGF monoclonal dy had a surprisingly long
elimination (beta) phase half life of approximately 9 days.
Figure 19 shows that anti-canine NGF monoclonal antibodies reduce inflammatory
pain in dogs. Kaolin was injected into the footpad of beagle dogs at Day -1,
antibody or vehicle control at Day 0 and lameness was measured by a visual
scoring scale.
Detailed description of the Invention
ing extensive experimentation, the inventor has taken the rat anti-mouse
NGF monoclonal antibody (MAb) dD11 amino acid ce and surprisingly
used this to produce a non-immunogenic anti-canine NGF antibody. The resulting
non-immunogenic antibody, which is not produced using standard CDR grafting
techniques, is shown to exhibit high affinity binding to canine NGF. The antibody
neutralises canine NGF biological function, most specifically by inhibiting the
binding of NGF to cell based receptors TrkA and p75. Furthermore, it has also
been discovered, unexpectedly, that when stered to a , neutralising
antibodies are not produced there against. Accordingly, the caninised antibody of
the invention is suitable for long term chronic pain relief in dogs.
The s of generating the heavy and light chain variable domains for the
antibodies of the invention which has been employed by the inventor results in the
replacement of specific rat (donor) amino acid residues which are present within
the framework regions of the light and heavy chain variable domains with es
which, based on the inventor’s is, will retain the conformation of the CDR
regions and therefore maintain binding specificity and avidity, while reducing the
presence of immunogenic epitopes which may result in neutralising antibodies
being generated against the antibody, if it were to be administered to canines in an
unaltered form. Specifically, the method of preparing antibodies of the invention
(known as PETisation) ses assessing the ce of the framework
regions of a donor (e.g. rat) dy for suitability for administering to a canine by
ing the sequence of the framework regions of the donor antibody with the
sequence of an antibody or a pool of antibodies derived from canines. Although
the comparison may be between the donor sequence and a single member of the
target sequence, it will be obvious that comparison with a pool of target sequences
is preferred because this will expand the number of natural options at each Kabat
position in the target species. Not only will this increase the chance of a “match”
n the donor and the target, but it will also expand the options for
replacement where a match does not exist. As a , a replacement with
characteristics as close as possible to the donor will be able to be chosen. Where
the donor sequence and the canine sequence differ at any Kabat number or
corresponding position, the donor sequence is modified to substitute the amino
acid residue in question with an amino acid residue which is known to be natural at
that position in canines.
Where substitution of an amino acid residue present in a donor globulin
framework region is required, typically this is undertaken using the principle of
vative substitution wherein an amino acid residue is replaced with an amino
acid residue which is natural at that Kabat on in a canine and is as closely
related as possible in size, charge and hobicity to the amino acid being
substituted in the donor sequence. The intention is to choose a replacement
which would cause no, or at least only minimum, bation or disruption to the
three-dimensional structure of the donor antibody. In n situations, there will
be no clear option and each choice will have benefits and downsides. A final
on may require three-dimensional modelling or even expression of various
alternative sequences. However, generally, a clear preference will be available.
As a result of this ure, a change in the donor sequence is only made when
that residue would be foreign in the target and the replacement amino acid is as
closely related as possible to that which it replaces. Thus, the on of foreign
epitopes is avoided, but the overall three-dimensional structure is preserved and
as a result, affinity and specificity are also preserved.
The light and heavy chain constant regions are typically derived from canine
(target) derived antibodies. The heavy chain constant domains are selected or
modified such that they do not e downstream effector functions. As it has
been found, quite surprisingly, that no or minimal neutralising antibodies are
produced against the antibodies produced according to the ion, the
antibodies have surprisingly been found to have the associated benefit of long
circulatory half life and the option for repeat dosing. Furthermore, as the
substitution of the framework residues is performed in such a manner that it does
not affect the three dimensional conformation of the CDR s, there will be no
variation in binding specificity to the desired target.
There are four major lgG isotypes in man and mouse and while nomenclature is
similar they differ in behaviour and function including affinity for bacterial products
such as Protein A and Protein G, their ability to te the complement
dependent cytolysis (CDC) and their ability to induce killing of target cells through
antibody dependent cellular xity (ADCC). The ion of lgG isotypes with
CDC and ADCC active or “armed” constant domains is considered to be of clinical
benefit when antibodies are designed to eliminate target cells bearing their
cognate antigen, such as in oncology or infection control (e.g. in human medical
use human lgG1 isotypes are preferred for the above purposes). By contrast, the
activation of the immune system is considered undesirable in other settings such
as in the relief of inflammation, pain or munity and so human lgG isotypes
with minimal CDC and ADCC activity are red (e.g. in such human medical
use, lgG4 isotypes are often preferred). Four distinct immunoglobulin gamma
(lgG) heavy chain constant domain isotypes have been described in the canine
immune system (US Patent No. 5,852,183, Tang L. et al. 2001. Veterinary
Immunology and lmmunopathology, 80. 259-270) along with single kappa and
lambda constant domain ces. The four canine heavy chain constant
domains A, B, C and D have not been characterised in terms of functional activity
mediated thereby. Despite overall homology to the lgG family, the proteins
encoding canine lgG are more related to one r than to family members from
other species, so it has not been possible by homology alone to define which of
the above functions if any can be ascribed to each of the four canine isotypes.
The selection of lgG isotypes with CDC and ADCC active nt domains is
considered to be of benefit when antibodies are designed to eliminate target cells
bearing the cognate antigen, such as in oncology or infection control, e.g. in
human medical use human lgG1 isotypes are preferred. By st, the
activation of the immune system is considered undesirable in other settings such
as in the relief of inflammation, pain or autoimmunity and so human lgG isotypes
with minimal or “disarmed” CDC and ADCC activity are preferred, e.g. in human
medical use, lgG4 isotypes would be selected.
The antibodies of the invention comprise canine d heavy and light chain
constant domains. Furthermore, the complementarity determining s are
derived from the rat alphaD11 anti-mouse NGF antibody. The dD11 antibody was
first described by eo et al. (Cattaneo A, Rapposelli B, Calissano P. (1988)
“Three distinct types of monoclonal antibodies after long-term immunization of rats
with mouse nerve growth factor”. J Neurochem 50(4):1003-1010). The alphaD11
dy was subsequently cloned by Ruberti et al. ti, F. et al. (1993)
“Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for
Studies Using the ntibody Approach”. ar and Molecular Neurobiology.
13(5):559-568).
The CDR regions derived from the dD11 antibody are combined with framework
region sequences which have been determined by the inventor to preserve CDR
tertiary structure, and therefore g specificity, while preventing neutralising
antibodies being raised there against, when the antibody is stered to a
canine.
Each of the light and heavy chain variable regions contains four framework
regions, referred to as FR1-FR4. For each of these framework regions, the
inventor has identified a preferred amino residue (a so called preferred residue) for
each ic position, and furthermore alternative amino acid residues which
could also be provided at that position. Tables 1 to 8 below illustrate the 4
framework regions for each of the heavy and light chains. The tables provide the
amino acid position relative to that specific framework region and further according
to the Kabat numbering system used to identify the position of a particular residue
along the length of the te heavy or light chain variable domain. The residue
or residues shown as group 1 es are the preferred residues, while the group
2 residues are alternative residues. However these would generally not be
able to the residues shown in group 1 relating to that specific position. The
amino acid residues are identified using the single letter system.
Table 1 — Light chain variable domain FR1 residues
Light Kabat light Group 1 Group 2
chain FR1 chain amino acid amino
position numbering residues acid
position residues
1 1 D
2 2 l
3 3 QV
4 4 M
5 TM |
6 6 Q
7 7 ST
8 8 P
9 9 AL P
10 S
11 11 L
12 12 S A
13 13 LV
14 14 S RT
15 QPR
16 16 GE D
17 17 E D
18 18 TKP AEL
19 19 VA
20 TS
21 21 |
22 22 ST Y
23 23 C Y
Table 2 — Light chain variable domain FR2 residues
Light Kabat light Group 1 Group 2
chain FR2 chain amino acid amino
position ing residues acid
position residues
1 35 W
2 36 YF IL
3 37 QR IL
4 38 Q H
39 K R
6 40 P AS
7 41 G D
8 42 Q
9 43 SA PT
44 P
1 1 45 KO ER
12 46 LR AGPS
13 47 L
14 48 | L
49 Y EFNSV
Table 3 — Light chain variable domain FR3 residues
Light Kabat light Group 1 Group 2
chain FR3 chain amino acid amino
position numbering residues acid
on residues
1 57 G A
2 58 V A
3 59 P S
4 60 SD
61 R
6 62 F LV
7 63 S |
8 64 G A
9 65 S
66 G
11 67 S
12 68 G
13 69 T A
14 70 DE
71 FY
16 72 ST R
17 73 FL
18 74 KT R
19 75 |
76 SN
21 77 S
22 78 LV
23 79 E
24 80 PS A
81 E DGIN
26 82 D
27 82A VA GST
28 82B A G
29 820 V IL
83 Y
31 84 YF
32 85 C
Table 4 — Light chain le domain FR4 residues
Light Kabat light Group 1 Group 2
chain FR4 chain amino acid amino
position numbering residues acid
position residues
1 95 F
2 96 G S
3 97 A PQT
4 98 G E
99 T P
6 100 K 08
7 101 V LW
8 102 ED R
9 103
104
Table 5 — Heavy chain variable domain FR1 es
Heavy Kabat heavy Group 1 Group 2
chain FR1 chain amino acid amino
position numbering residues acid
position residues
1 1 E DG
2 2 V EGILM
3 3 Q AEHKLP
4 4 L PV
5 V AELM
6 6 E A0
7 7 S FLT
8 8 G
9 9 G E
10 GD AENT
11 11 L QRVW
12 12 V AIM
13 13 ON KR
14 14 P FT
15 GT AE
16 16 GE A
17 17 ST P
18 18 L R
19 19 RT GKV
20 L N
21 21 S Y
22 22 C
WO 53121
23 23 V AEIL
24 24 AIV GST
25 S GPT
26 26 G DRT
27 27 F DILSTV
28 28 ST ADILMN
29 29 LF IMV
30 ST DGHIKN
Table 6 — Heavy chain variable domain FR2 residues
Heavy Kabat heavy Group 1 Group 2
Chain FR2 chain Amino Acid Amino
position numbering residues Acid
position residues
1 36 W C
2 37 V AFIL
3 38 R
4 39 Q HL
40 A DGPSTV
6 41 LP
7 42 G ELR
8 43 RK AEGMQ
9 44 G DERTV
45 L FMP
11 46 E0 DHLPR
12 47 W CFLMSY
13 48 V FIL
14 49 GA LST
Table 7 — Heavy chain variable domain FR3 residues
Heavy Kabat heavy Group 1 Group 2
chain FR3 chain amino acid amino
position numbering residues acid
on residues
1 66 R Q
2 67 LF V
3 68 T AIS
4 69 | LMTV
70 ST AF
6 71 R K
7 72 D EN
8 73 TN DGIS
9 74 AS DGPTV
75 K EGMNQ
11 76 SN DHKR
12 77 T AIMS
13 78 VL AIM
14 79 FY HST
80 L |
16 81 KO ADEHR
17 82 M L
18 82A HN DKPRST
19 82B S DGNRT
820 L V
21 83 QR GIKST
22 84 SA DGPTV
23 85 E ADV
24 86 D
87 T AMS
26 88 A GV
27 89 TV FIKLMQ
28 90 Y H
29 91 Y FH
92 C
31 93 A CGLMRS
32 94 RK ADEGIL
MNPQST
Table 8 — Heavy chain variable domain FR4 es
Heavy Kabat heavy Group 1 Group 2
Chain FR4 chain Amino Acid Amino
position numbering residues Acid
position residues
1 103 W L
2 104 G AS
3 105 Q DHPR
4 106 G
107 T AINS
6 108 SL PQR
7 109 V ILP
8 110 T AFILPSY
9 111 V A
112 S ACPT
11 113 S ALP
The caninised antibody of the ion therefore differs from, for example, a
chimeric monoclonal antibody which consists of a complete variable region derived
WO 53121
from a first species and constant domains derived from a second species, or from
a CDR-grafted sed antibody, where the complementarity determining
regions (CDRs) of the heavy and light chain variable regions se amino acid
residues derived from a donor antibody and introduced into ork s
(FR) and constant regions (CR) derived from a target antibody or from canine
germline sequences.
It is preferred that the caninised antibody substantially retains the binding
properties of the parent (donor) antibody from which the CDRs are derived. That
means that the caninised dy will exhibit the same or substantially the same
antigen-binding ty and avidity as the donor antibody from which the CDRs are
derived. Ideally, the affinity of the caninised dy will not be less than 10% of
the donor antibody affinity for the target epitope, more preferably not less than
about 30%, and most preferably the affinity will not be less than 50% of the parent
(donor) dy. Methods for assaying antigen-binding affinity are well known in
the art and include half-maximal binding assays, competition assays, and
Scatchard analysis.
As defined hereinbefore, the present invention extends to binding members or
antigen binding fragments derived from the caninised antibodies of the invention.
Such antigen binding fragments refer to one or more fragments of an antibody that
retain the ability to specifically bind to canine NGF. It has been shown that the
n binding function of an dy can be performed by fragments of a full
length antibody. In certain embodiments, the binding members or antigen binding
fragments may be isolated binding members. A binding member or n
binding nt of the invention may comprise a fragment of the antibodies of the
present invention, e.g. a fragment of a fully caninised antibody molecule, such as
the heavy or light chain only, or, for example, the variable domain of the heavy
and/or light chain. In certain embodiments, a binding member may typically
comprise, consist, or consist essentially of an antibody VH and/or VL domain. VH
domains of binding s are also provided as part of the invention. Within
each of the VH and VL domains are 3 complementarity determining regions
("CDRs"), along with 4 associated framework regions ("FRs"). A VH domain
typically comprises 3 HCDRs (heavy chain complementarity determining regions),
and a VL domain typically comprises 3 LCDRs (light chain complementarity
regions). Accordingly, a binding member may comprise a VH domain comprising,
in sequence, VH CDR1 (or HCDR1), CDR2 (HCDR2) and CDR3 (HCDR3) regions
along with a plurality of associated framework regions. A binding member may
additionally or alternatively comprise a VL domain comprising VL CDR1, CDR2
and CDR3 domains along with associated framework regions. The VH or VL
domains typically comprise fourframework regions, FR1, FR2, FR3 and FR4. As
used herein, the term "framework region" or "framework sequence" refers to the
remaining sequences of a variable region minus the CDRs. Because the exact
definition of a CDR sequence can be ined by different s (Kabat,
Chothia etc.), the g of a framework sequence is subject to correspondingly
different interpretations. The six CDRs (VL-CDR1, CDR2 and CDR3 of the light
chain and VH-CDR1, CDR2 and CDR3 of the heavy chain) divide the framework
regions on the light chain and the heavy chain into four sub-regions known as
FR1, FR2, FR3 and FR4 on each chain.
Figure 6 shows the amino acid sequence of a light chain variable domain of an
anti-NGF antibody ing to the invention. The CDR1, CDR2 and CDR3
regions are underlined. As such, and as shown in Figures 6 the VL-CDR1 is
positioned between FR1 and FR2 framework s, the VL-CDR2 is positioned
between the FR2 and FR3 framework s, and the VL-CDR3 is positioned
between the FR3 and FR4 framework s. Figure 7 shows the amino acid
sequence of a heavy chain variable domain of an anti-NGF antibody according to
the ion. The CDR1, CDR2 and CDR3 regions are underlined. As with the
light chain variable region shown in Figure 6, the 1 is positioned between
FR1 and FR2 framework regions, the VH-CDR2 is on between the FR2 and
FR3 framework regions, and the VH-CDR3 is positioned n the FR3 and
FR4 framework regions.
WO 53121 2012/051002
In Figures 6 and 7, the residues of the light chain variable domain (Figure 6) and
heavy chain variable domain (Figure 7) are conventionally numbered according to
the numbering system devised by Kabat et al. (Kabat,E.A., Wu,T.T., Perry,H.,
Gottesman,K. and r,C. (1991) Sequences of Proteins of Immunological
Interest, Fifth Edition. NIH ation No. 91-3242, Kabat et al. (1971) Ann. NY
Acad, Sci. 2—391). The Kabat numbering system refers to a system of
numbering amino acid residues which are more variable (i.e. hypervariable) than
other amino acid residues in the heavy and light chain variable regions of an
antibody, or an antigen g portion thereof. The Kabat numbering system is
therefore lly used when referring to a residue in the variable domain
(approximately residues 1-104 of the light chain and residues 1-113 of the heavy
chain). This numbering system may be used in the present specification, where
stated. The Kabat residue designations do not always correspond directly with the
linear numbering of the amino acid residues of the heavy and light chain variable
regions of the present invention ed in the relevant sequences listed herein.
In particular, the actual linear amino acid sequence may contain fewer or
additional amino acids than in the strict Kabat ing corresponding to a
shortening of, or insertion into, a structural component, whether a framework
region or complementarity determining region (CDR), of the basic variable domain
structure of the heavy or light chain. The correct Kabat numbering of residues
may be determined for any given antibody by alignment of residues in the
sequence of the antibody with a standard sequence to which the Kabat numbering
has been applied.
Furthermore, Figure 7 shows a heavy chain variable domain amino acid
sequence. This is also shown in SEQ ID NO:2. However, in Figure 7, the
numbering takes account of amino acid es 80, 80A, 80B, and 80C, whereas
in SEQ ID NO:2, the numbering continues sequentially, that is 80, 81, 82 and 83.
The same is true for Kabat residues 100, 100A, 100B, 100C, 100D, 100E and
100F in Figure 7.
As described hereinbefore, an antibody binding fragment may be selected from
the group comprising, but not limited to, a Fab fragment, a Fab’ fragment and a
scFv (single chain variable fragment), or from a peptidomimetic, a diabody, or a
related multivalent derivative.
In certain embodiments the antibody binding fragment is a Fab, or F(ab’)2
fragment, which consists of the VL, VH, CL and CH1 domains of an antibody. In
certain embodiments, the VL domain has an amino acid sequence of SEQ ID
NO:1 or SEQ ID NO:3, and the VH domain has an amino acid sequence of SEQ
ID NO:2 or SEQ ID NO:4. In certain embodiments, the CL and CH1 s are
based on the amino acid sequence of a CL and CH1 domain of a canine
immunoglobulin.
Techniques used for the recombinant production of Fab, Fab’ and F(ab’)2
fragments are well known to the person skilled in the art and include those
disclosed in International PCT Patent Publication WO 92/22324, and in Sawai et
al., “Direct tion of the Fab Fragment Derived From the Sperm Immobilizing
Antibody Using rase Chain Reaction and cDNA Expression Vectors”, 1995,
AJRI 34:26-34. Examples of techniques which can be used to produce scFv
e chain Fv fragments) are disclosed in Huston et al., “Protein Engineering of
Single-Chain Fv Analogs and Fusion Proteins”, s in logy, vol.
203:46-88 (1991), the contents of which are incorporated by reference.
In certain ments, antibody fragments can be derived from full length
antibodies by proteolytic digestion according to the method of Morimoto (Morimoto
et al., "Single-step cation of 2 fragments of mouse monoclonal
antibodies (immunoglobulins G1) by hydrophobic interaction high performance
liquid chromatography using TSngl Phenyl-5PW" Journal of mical and
Biophysical Methods 24:107-117 ). Antibody fragments can also be
produced directly by host cells (Carter et al., "High level Escherichia coli
expression and production of a bivalent humanized dy fragment"
Bio/Technology 10:163-167 (1992)).
WO 53121
In addition to providing a caninised monoclonal antibody which has binding
specificity to canine NGF and which antagonises canine NGF on, the present
invention further s to g members other than antibodies comprising a
pair of binding domains based on the amino acid sequence of a VL (light chain
variable) region as defined in SEQ ID NO:1 or SEQ ID NO:3 and an amino acid
sequence of a VH (heavy chain variable) region as defined in SEQ ID N02 or
SEQ ID NO:4. In particular, the invention s to single binding domains which
are based on either the VL or VH region of the caninised antibodies of the
antibodies of the invention.
Accordingly, in certain further embodiments of the t ion, there is
provided a binding member comprising, consisting or consisting essentially of a
single binding domain derived from the humanised antibody of the invention. In
certain ments, the single binding domain is derived from the amino acid
sequence of the VH (heavy chain variable domain) as defined in SEQ ID N02 or
SEQ ID NO:4. Such a binding domain may be used as a targeting agent to canine
NGF.
In certain embodiments, further engineering techniques can be used to modify the
antibodies of the present invention, for example by including modifications of the
Fc region which can alter serum half life, complement fixation, Fc receptor binding
and/or antigen dependent cellular cytotoxicity. r, in certain embodiments,
antibodies or antibody fragments can be produced which have d
glycosylation patterns. In certain embodiments, an antibody of the invention is
altered to increase or decrease the extent to which the antibody is glycosylated.
Glycosylation of polypeptides is typically either ed or O-linked. N-linked
refers to the attachment of a carbohydrate moiety to the side chain of an
asparagine residue. The tripeptide sequences asparagine-X-serine and
asparagine-X -threonine, where X is any amino acid except proline, are the
recognition sequences for enzymatic attachment of the ydrate moiety to the
asparagine side chain. Thus, the presence of either of these tripeptide sequences
2012/051002
in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers
to the attachment of one of the sugars N- aceylgalactosamine, galactose, or
xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-
yproline or 5-hydroxylysine may also be used. The inventor has provided
aglycosylated canine constant domains, these being d herein as SEQ ID
NO:15, 16, 17, 18, 19, 20, 21, and 22.
In certain r ments, the anine NGF antibodies of the invention
can be PEGylated by reacting the antibody with a plyethylene glycol (PEG)
derivative. In certain embodiments, the antibody is defucosylated and therefore
lacks fucose residues.
In certain embodiments, modifications in the biological properties of an antibody
may be accomplished by selecting substitutions that affect (a) the structure of the
polypeptide backbone in the area of the tution, for example, as a sheet or
l conformation, (b) the charge or hydrophobicity of the molecule at the target
site, or (c) the bulk of the side chain. Amino acids may be grouped according to
rities in the properties of their side chains (A. L. Lehninger, in Biochemistry,
2nd Ed., 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V),
Leu (L), lie (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G),
Ser (8), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q); (3) acidic: Asp (D), Glu (E); (4)
basic: Lys (K), Arg (R), His(H). Alternatively, naturally occurring residues may be
divided into groups based on common side-chain properties: (1) hydrophobic:
Norleucine, Met, Ala, Val, Leu, lie; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;
(3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain
orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions
will entail exchanging a member of one of these classes for another class. Such
substituted residues also may be introduced into the conservative substitution
sites or, into the remaining (e.g., non-conserved) sites.
In various further aspects, the present ion extends to an immunoconjugate
comprising an anti-canine NGF antibody of the ion, or an antigen binding
portion thereof linked to a partner molecule. In certain ments, such an
antibody-partner molecule conjugate is conjugated by means of a chemical linker,
such as a peptidyl linker, a hydrazine linker or a disulphide linker. In certain
embodiments, the coupling partner is an effector molecule, label, drug, or carrier
molecule. Suitable techniques for coupling the dies of the ion to both
peptidyl and non-peptidyl coupling partners will be well known to persons skilled in
the art. Examples of suitable labels include detectable labels, such as a
radiolabel, or an tic label, such as horse radish peroxidase, or chemical
moieties, such as . atively, the label may be a functional label, for
example, ricin, or pro-drugs which are capable of converting prodrugs into active
drugs at the site of antibody binding.
In various further aspects, the present invention extends to polynucleotides, and in
particular isolated polynucleotides, which encode the caninised antibodies,
antibody fragments and binding members of the present invention. As defined
herein, a “polynucleotide” includes any polyribonucleotide or
polydeoxyribonucleotide, which may be unmodified RNA or DNA, or ed RNA
or DNA, including without tion, single and double stranded RNA, and RNA
which is a mixture of single and double stranded regions. A polynucleotide of the
invention, e.g. a cleotide which encodes a polypeptide or polypeptides of
the invention includes c variants thereof and/or their complements including a
polynucleotide that hybridises to such nucleotide sequences under conditions of
te or high stringency.
The t invention further extends to dy mimetics, such as domain
antibodies, nanobodies, unibodies, versabodies, and duocalins which are based
on the canine NGF antibodies of the present invention. A wide variety of antibody
mimetic technologies are known to the person skilled in the art. For example, so
called, domain antibodies (Domantis, UK) are small functional binding units of
antibodies which correspond to the variable regions of either the light or heavy
chains of human antibodies. Directions for the tion of such domain
antibodies can be found in US Patent No. 6,291,158, US Patent No. 6,582,915
2012/051002
and US Patent No. 6,593,081. Nanobodies are dy-derived therapeutic
proteins which contain unique ural and functional properties of naturally
occurring heavy chain antibodies found in camelids. Unibodies are a further
dy fragment technology, based upon the removal of the hinge region of lgG4
antibodies. The deletion of the hinge region results in a molecule which is
approximately half the size of a ional lgG4 dy and which has a
univalent binding region. Unibodies ve the property of lgG4 antibodies of
being inert and therefore not inducing immune responses.
Further binding molecules include affibody molecules (US Patent 5,831,012),
DARPins (designed ankyrin repeat proteins) (International PCT Patent Application
Publication WO 02/20565) and anticalins (US Patent No. 7,250,297 and WO
99/16873). dies are a further antibody mimetic technology. Versabodies
(Amunix, US Patent Application Pubtication No. 2937.:‘(319127’3 are small proteins,
referred to as microproteins, of 3-5kDa with greater than 15% cysteine residues,
which form a high disulphide bond density scaffold which replaces the hydrophobic
core which protein typically exhibit
Avimers are r type of antibody mimetic. Avimers originate from the
recombination of families of human serum proteins. They are single protein chains
composed of modular binding s, each of which is ed to bind to a
particular target site. The avimers can bind simultaneously to sites on a single
n target and/or sites on le protein targets. Known as multi-point
attachment or avidity, this binding mechanism mimics the way cells and molecules
interact in the body, supports the generation of antagonists and agonists, and
results in drugs with multiple functions and potent activity. Avimers libraries can
be produced according to incorporated herein by reference and
for example US 2005/0053973. Avimers libraries are also available commercially
from Avidia Inc, Mountain View, California, USA.
Antibody production
The antibodies and binding members of the invention may be produced wholly or
partly by chemical synthesis. For example, the antibodies and g members
of the invention can be prepared by techniques which are well known to the
person skilled in the art, such as standard liquid peptide synthesis, or by solid-
phase peptide synthesis methods. Alternatively, the antibodies and binding
members may be prepared in solution using liquid phase peptide synthesis
techniques, or further by a ation of solid-phase, liquid phase and solution
chemistry.
The present invention further extends to the tion of the antibodies or binding
members of the invention by expression of a nucleic acid which encodes at least
one amino acid which ses an antibody of the invention in a suitable
sion system, such that a desired peptide or polypeptide can be encoded.
For example, a nucleic acid encoding the amino acid light chain and a second
nucleic acid encoding an amino acid heavy chain can be expressed to provide an
antibody of the present ion.
Accordingly, in n further aspects of the invention, there is provided nucleic
acids encoding amino acid sequences which form the antibodies or binding
members of the present invention.
Typically, nucleic acids encoding the amino acid sequences which form antibodies
or g members of the present invention can be ed in an isolated or
purified form, or provided in a form which is substantially free of material which can
be naturally associated with it, with the exception of one or more tory
sequences. Nucleic acid which expresses an antibody or binding member of the
invention may be wholly or partially synthetic and may e, but is not limited to
DNA, cDNA and RNA.
Nucleic acid sequences ng the antibodies or binding members of the
invention can be readily prepared by the skilled person using techniques which are
well known to those skilled in the art, such as those described in Sambrook et al.
“Molecular Cloning”, A laboratory manual, cold Spring Harbor Laboratory Press,
Volumes 1-3, 2001 (ISBN-0879695773), and l et al. Short Protocols in
Molecular Biology. John Wiley and Sons, 4th Edition, 1999 (ISBN — 0471250929).
Said techniques e (i) the use of the polymerase chain reaction (PCR) to
amplify samples of nucleic acid, (ii) chemical synthesis, or (iii) preparation of cDNA
sequences. DNA encoding antibodies or binding members of the invention may
be generated and used in any suitable way known to those skilled in the art,
including taking encoding DNA, identifying suitable restriction enzyme recognition
sites either side of the portion to be expressed, and cutting out said n from
the DNA. The excised portion may then be operably linked to a suitable promoter
and expressed in a le expression system, such as a commercially available
expression system. Alternatively, the relevant portions of DNA can be amplified by
using suitable PCR primers. Modifications to the DNA sequences can be made by
using site directed mutagenesis.
Nucleic acid sequences ng the antibodies or binding members of the
invention may be provided as constructs in the form of a plasmid, vector,
transcription or expression cassette which ses at least one nucleic acid as
described above. The construct may be comprised within a recombinant host cell
which comprises one or more constructs as above. Expression may conveniently
be achieved by culturing, under appropriate conditions, recombinant host cells
containing le c acid sequences. Following expression, the antibody or
antibody fragments may be isolated and/or purified using any suitable technique,
then used as appropriate.
Systems for g and expression of a polypeptide in a variety of different host
cells are well known. le host cells include bacteria, mammalian cells, yeast,
insect and baculovirus systems. Mammalian cell lines available in the art for
sion of a heterologous polypeptide e Chinese hamster ovary (CHO)
cells, HeLa cells, baby hamster kidney cells and NSO mouse myeloma cells. A
common, preferred bacterial host is E. coli. The sion of antibodies and
antibody fragments in prokaryotic cells such as E. coli is well established in the art.
Expression in eukaryotic cells in culture is also available to those skilled in the art
as an option for production of a binding member.
General techniques for the production of antibodies are well known to the person
skilled in the field, with such methods being sed in, for example, Kohler and
Milstein (1975) Nature 256: 495-497; US Patent No. 4,376,110; Harlow and Lane,
Antibodies: a Laboratory Manual, (1988) Cold Spring Harbor. Techniques for the
preparation of recombinant antibody molecules are bed in the above
references and also in, for example, European Patent Number 0,368,684.
In certain embodiments of the invention, recombinant nucleic acids comprising an
insert coding for a heavy chain variable domain and/or for a light chain le
domain of antibodies or binding members are employed. By definition, such
nucleic acids comprise encode single stranded nucleic acids, double stranded
nucleic acids consisting of said coding nucleic acids and of complementary nucleic
acids thereto, or these complementary e stranded) nucleic acids themselves.
Furthermore, nucleic acids encoding a heavy chain variable domain and/or a light
chain variable domain of antibodies can be enzymatically or chemically
synthesised nucleic acids having the authentic sequence coding for a naturally-
occurring heavy chain variable domain and/or for the light chain le domain,
or a mutant thereof.
An antibody of the ion may be produced by recombinant means, not only
ly, but also as a fusion polypeptide with a heterologous polypeptide, which is
preferably a signal sequence or other polypeptide having a specific cleavage site
at the N-terminus of the mature protein or polypeptide. The logous signal
sequence selected ably is one that is recognized and processed (i.e.,
cleaved by a signal ase) by the host cell. For prokaryotic host cells that do
not recognize and process a native antibody signal sequence, the signal sequence
is substituted by a prokaryotic signal sequence selected, for example, from the
group of the alkaline phosphatase, llinase, |pp, or heat-stable toxin ll
leaders.
The term “isolated”, when used in reference to the caninised dies of the
invention, or to binding s derived therefrom, or polypeptides which encode
the same, refers to the state in which said antibodies, binding members or nucleic
acids (polynucleotides) are provided in an isolated and/or purified form, that is they
have been separated, isolated or purified from their natural environment, and are
provided in a substantially pure or homogeneous form, or, in the case of nucleic
acid, free or substantially free of nucleic acid or genes of origin other than the
sequence encoding a polypeptide with the ed function. Accordingly, such
isolated antibodies, g members and isolated nucleic acids will be free or
substantially free of material with which they are naturally associated, such as
other polypeptides or nucleic acids with which they are found in their natural
environment, or the environment in which they are prepared (e.g. cell culture)
when such preparation is by recombinant DNA technology sed in vitro or in
vivo.
Antibodies, binding members and nucleic acids may be formulated with diluents or
adjuvants and still, for practical purposes, be considered as being provided in an
ed form. For example the dies and binding members can be mixed
with gelatin or other carriers if used to coat microtitre plates for use in
immunoassays, or will be mixed with pharmaceutically acceptable carriers or
diluents when used in diagnosis or therapy. The antibodies or g members
may be glycosylated, either naturally or by systems of heterologous eukaryotic
cells (e.g. CHO or NSO cells, or they may be (for example if produced by
expression in a prokaryotic cell) osylated.
Heterogeneous preparations comprising anti-canine NGF caninised antibody
molecules also form part of the invention. For example, such preparations may be
es of antibodies with full-length heavy chains and heavy chains lacking the
C-terminal lysine, with various degrees of glycosylation and/or with derivatized
amino acids, such as cyclization of an N-terminal glutamic acid to form a
utamic acid residue.
Purification of Antibodies
Canine anti-NGF MAbs isotypes A, B, C and D are equipotent. Canine lgG
isotypes A and D may be preferred for use in the present ion as these
es have a desirable lack of binding to complement. However, these isotypes
do not bind Staphylococcus Protein A or ococcal Protein G and so cannot be
purified using these common tools. The inventors of the t invention have
identified two alternative methods which can be used to purify isotypes A and/or D.
The first method comprises a combination of anion exchange chromatography,
hydrophobic interaction chromatography and size ion chromatography. The
second method comprises a ation of captoadhere affinity chromatography
and anion exchange chromatography.
Pharmaceutical compositions
Typically the pharmaceutical compositions of the invention are formulated in a
liquid formulation, a lized formulation, a lyophilized formulation that is
reconstituted as a liquid, or as an aerosol formulation. In certain embodiments,
the antibody in the formulation is at a concentration of: about 0.5 mg/ml to about
250 mg/ml, about 0.5 mg/ml to about 45 mg/ml, about 0.5 mg/ml to about 100
mg/ml, about 100 mg/ml to about 200 mg/ml, or about 50 mg/ml to about 250
mg/ml.
In certain embodiments, the formulation further comprises a buffer. Typically the
pH of the formulation is from about pH 5.5 to about pH 6.5. In certain
embodiments, the buffer may comprise from about 4 mM to about 60 mM histidine
buffer, about 5 mM to about 25 mM succinate buffer, or about 5 mM to 25 mM
acetate buffer. In n embodiments, the buffer comprises sodium chloride at a
concentration of from about 10mM to 300mM, typically at around 125mM
concentration and sodium citrate at a concentration of from about 5mM to 50mM,
typically 25mM. In certain embodiments the formulation can further comprise a
surfactant at a concentration ofjust above 0% to about 0.2%. In certain
embodiments the surfactant is selected from the group consisting of, but not
limited to: polysorbate-20, polysorbate-40, polysorbate-60, rbate-65,
polysorbate-80, polysorbate-85, and ations thereof. In a preferred
embodiment, the surfactant is polysorbate-20 and may further comprise sodium
chloride at a concentration of about 125mM and sodium citrate at a concentration
of about 25mM.
Administration
The antibodies or binding s of the present invention may be stered
alone but will preferably be stered as a ceutical composition which
will generally comprise a suitable pharmaceutically acceptable excipient, diluent or
r selected depending on the intended route of administration. Examples of
suitable pharmaceutical carriers include; water, glycerol, ethanol and the like.
The monoclonal dy or g member of the present invention may be
administered to a canine patient in need of treatment via any suitable route.
Typically, the composition can be administered parenterally by injection or
infusion. Examples of preferred routes for parenteral administration include, but
are not limited to; intravenous, intracardial, intraarterial, intraperitoneal,
intramuscular, intracavity, subcutaneous, transmucosal, inhalation or transdermal.
Routes of administration may further include topical and enteral, for example,
mucosal (including pulmonary), oral, nasal, rectal.
ln embodiments where the composition is delivered as an injectable composition,
for example in intravenous, intradermal or aneous application, the active
ingredient can be in the form of a parenterally acceptable aqueous on which
is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant
skill in the art are well able to prepare suitable solutions using, for example,
ic vehicles such as sodium chloride injection, Ringer’s injection or, Lactated
Ringer’s injection. Preservatives, stabilisers, buffers, antioxidants and/or other
additives may be included, as required.
The composition may also be administered via microspheres, liposomes, other
microparticulate delivery systems or sustained release formulations placed in
certain tissues including blood.
Examples of the techniques and ols mentioned above and other techniques
and protocols which may be used in ance with the invention can be found in
Remington’s Pharmaceutical Sciences, 18th edition, Gennaro, A.R., Lippincott
Williams & s; 20th edition ISBN 004-3 and Pharmaceutical Dosage
Forms and Drug Delivery Systems; Ansel, H.C. et al. 7th Edition ISBN 0
72-7, the entire disclosures of which is herein incorporated by reference.
The antibodies and compositions of the invention are typically administered to a
subject in a “therapeutically effective ”, this being an amount sufficient to
show benefit to the subject to whom the composition is administered. The actual
dose administered, and rate and time-course of administration, will depend on,
and can be ined with due reference to, the nature and ty of the
condition which is being treated, as well as factors such as the age, sex and
weight of the subject being d, as well as the route of administration. Further
due consideration should be given to the properties of the composition, for
example, its binding activity and in-vivo plasma life, the concentration of the
antibody or binding member in the formulation, as well as the route, site and rate
of delivery.
Dosage regimens can e a single administration of the antibody or
composition of the invention, or multiple administrative doses of the antibody or
composition. The antibody or antibody containing compositions can further be
administered sequentially or separately with other therapeutics and medicaments
which are used for the treatment of the ion for which the antibody or binding
member of the present invention is being administered to treat.
Examples of dosage regimens which can be administered to a subject can be
selected from the group comprising, but not limited to; 1ug/kg/day h to
20mg/kg/day, 1ug/kg/day through to 10mg/kg/day, 10ug/kg/day through to
/day. In certain embodiments, the dosage will be such that a plasma
concentration of from 1ug/ml to 100ug/ml of the antibody is obtained. However,
the actual dose of the ition administered, and rate and time-course of
stration, will depend on the nature and severity of the condition being
treated. Prescription of treatment, e.g. decisions on dosage etc, is ultimately
within the responsibility and at the discretion of veterinary practitioners and other
veterinary doctors, and typically takes account of the disorder to be treated, the
condition of the individual patient, the site of ry, the method of administration
and other factors known to practitioners.
Definitions
Unless otherwise defined, all technical and scientific terms used herein have the
meaning commonly understood by a person who is skilled in the art in the field of
the present invention. The g and scope of the terms should be clear,
however, in the event of any ambiguity, definitions provided herein take precedent
over any dictionary or extrinsic tion.
Throughout the specification, unless the context demands otherwise, the terms
“comprise“ or de“, or ions such as “comprises“ or “comprising“,
“includes“ or ding“ will be understood to imply the inclusion of a stated integer
or group of integers, but not the exclusion of any other integer or group of integers.
As used herein, terms such as "a an" and "the" include ar and plural
referents unless the context clearly demands otherwise. Thus, for example,
reference to "an active agent" or "a pharmacologically active agent" includes a
single active agent as well as two or more different active agents in combination,
while references to "a carrier" includes mixtures of two or more carriers as well as
a single carrier, and the like. Further, unless otherwise required by t,
singular terms shall include pluralities and plural terms shall include the singular.
As herein defined, the term “pain” means an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or described in
terms of such damage.
In relation to operative or post-operative pain, the US Animal Welfare Act (Animal
Welfare Act 2002. AWA regulations, CFR, Title 9 (Animals and Animal Products),
r 1 l and Plant Health Inspection Service, Department of
Agriculture). pter A (Animal Welfare), Parts 1—4) defines a painful
procedure as any procedure that would reasonably be expected to cause more
than slight or momentary pain or distress in a human being to which that
procedure was applied, that is, pain in excess of that caused by injections or other
minor procedures. Therefore, if a canine undergoes a painful al procedure,
the animal should receive erative sics.
In further instance, a canine may be experiencing significant or chronic pain as a
result of an associated medical condition such as rheumatoid arthritis,
osteoarthritis, inflammation or a cancerous or malignant condition.
The term “nociception” refers to the tion of noxious stimuli. As herein
defined “neuropathic pain” (also known as 'neuralgia') is a pain that comes from
problems with signals from the nerves. It may arise as a uence of a lesion
or disease affecting the somatosensory system. There are causes of neuropathic
pain and it may be associated with abnormal sensations called dysesthesia, which
occur spontaneously. Alternatively, it may be associated with nia which
results when the pain comes on, or gets worse, with a touch or us that would
not normally cause pain. For example, a slight touch on the face may trigger pain if
you have trigeminal neuralgia, or the pressure of the bedclothes may trigger pain if
you have diabetic neuropathy. Neuropathic pain may also result from allodynia,
where the pain comes on, or gets worse, with a touch or stimulus that would not
normally cause pain. For example, a slight touch to the face may trigger pain if a
subject has inal neuralgia. Neuropathic pain relating to hyperalgesia means
that severe pain results from a stimulus or touch that would normally cause only
slight discomfort, while paresthesia means that uncomfortable or painful feelings
occur even when there is nothing in contact with the area causing the pain, for
example pins and needles. Other forms of neuropathic pain involve pruritis or itch,
which can be associated with allergic or inflammatory responses in the skin and
inflammatory pain resulting from tissue damage and repair processes.
As defined herein, the term “NGF neutralising dy“ or similar describes an
dy that is capable of neutralising the ical activation and signalling of
NGF. The neutralising dy, which may also be referred to as an antagonistic
antibody, or a blocking antibody, specifically, and preferably selectively, binds to
NGF and inhibits one or more biological activities of NGF. For example, the
neutralising antibody may t the binding ofa NGF to its target ligand, such as
the cell membrane bound TrkA or p75 receptors.
As used herein, the term "biological activity" refers to any one or more inherent
biological properties of a molecule (whether present naturally as found in vivo, or
provided or enabled by recombinant means). Biological properties include but are
not d to receptor binding and/or tion; induction of cell signalling or cell
proliferation, inhibiting cell growth, induction of ne production, induction of
apoptosis, and enzymatic activity.
The term “complementarity determining region (CDR)“, as used herein, refers to
amino acid ces which together define the binding affinity and specificity of
the natural Fv region of a native immunoglobulin binding site as delineated by
Kabat et al. (Kabat,E.A., Wu,T.T., Perry,H., Gottesman,K. and Foeller,C. (1991)
Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication
No. 91-3242). The term “framework region (FR)“, as used , refers to amino
acid sequences interposed between CDRs. These portions of the antibody serve
to hold the CDRs in appropriate orientation (allows for CDRs to bind antigen).
The term ant region (CR)“ as used herein, refers to the portion of the
antibody molecule which confers effector functions. In the present invention,
constant regions typically mean canine constant s, that is that the nt
regions of the subject canininsed antibodies are derived from canine
immunoglobulins. The heavy chain constant region can be selected from any of
the four es: A, B, C or D.
The term “chimeric antibody“ as used herein refers to an antibody containing
sequences derived from two different antibodies, which lly are of different
species. Most typically chimeric antibodies comprise variable domains derived
from a donor specifies which bind specifically to a target epitope and constant
domains derived from antibodies obtained from the target species to whom the
antibody is to be administered.
The term “immunogenicity“ as used herein refers to a measure of the ability of a
targeting protein or therapeutic moiety to elicit an immune response (humoral or
cellular) when administered to a ent. The present invention is concerned with
the immunogenicity of the subject caninised antibodies. Preferably the antibodies
of the t invention have no immunogenicity, that is that no neutralising
antibodies will be raised against them when administered to a canine, and further,
no effector functions are mediated by the Fc regions of the antibody.
The term ity” or “sequence identity” as used herein, means that at any
particular amino acid residue position in an aligned sequence, the amino acid
residue is identical between the aligned sequences. The term arity” or
“sequence rity” as used herein, indicates that, at any particular position in the
aligned sequences, the amino acid residue is of a similar type between the
sequences. For example, e may be substituted for an isoleucine or valine
residue. This may be referred to as conservative substitution. Preferably when
the amino acid sequences of the ion are ed by way of conservative
substitution of any of the amino acid residues contained therein, these changes
WO 53121
have no effect on the binding specificity or functional activity of the ing
antibody when compared to the unmodified antibody.
Sequence ty with respect to a (native) polypeptide of the invention and its
functional derivative s to the percentage of amino acid residues in the
candidate sequence which are identical with the residues of the corresponding
native polypeptide, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percentage homology, and not considering
any conservative substitutions as part of the sequence identity. Neither N- or C-
terminal extensions, nor insertions shall be construed as reducing sequence
identity or homology. s and computer programs for performing an
alignment of two or more amino acid sequences and determining their ce
identity or homology are well known to the person skilled in the art. For example,
the tage of identity or similarity of 2 amino acid sequences can be readily
calculated using algorithms e.g. BLAST (Altschul et al. 1990), FASTA (Pearson &
Lipman 1988), or the Smith-Waterman algorithm (Smith & Waterman 1981).
As used , reference to an amino acid residue having the “highest homology”
to a second amino acid residue refers to the amino acid residue which has the
most characteristics or properties in common with the second amino acid residue.
In determining whether an amino acid e has the highest homology to a
second amino acid residue, an assessment may typically be made of factors such
as, but not limited to, charge, polarity, hydrophobicity, side arm mass and side arm
dimension.
The term “corresponding position” as used herein to refer to an amino acid residue
that is present in a second sequence at a position corresponding to a specified
amino acid residue in a first sequence is intended to refer to the position in the
second sequence which is the same position as the position in the first sequence
when the two sequences are aligned to allow for maximum sequence ty
between the two sequences. Amino acid residues at ponding positions
have the same Kabat numbering.
WO 53121
The term “consists essentially of’ or “consisting essentially of’ as used herein
means that a polypeptide may have additional features or elements beyond those
described provided that such additional features or elements do not materially
affect the ability of the antibody or antibody nt to have binding specificity to
canine NGF. That is, the antibody or antibody fragments sing the
polypeptides may have additional features or elements that do not ere with
the ability of the antibody or antibody fragments to bind to canine NGF and
antagonise canine NGF functional activity. Such modifications may be introduced
into the amino acid ce in order to reduce the immunogenicity of the
antibody. For example, a polypeptide consisting essentially of a specified
sequence may n one, two, three, four, five or more additional, deleted or
substituted amino acids, at either end or at both ends of the sequence provided
that these amino acids do not interfere with, t, block or upt the role of
the antibody or fragment in binding to canine NGF and sequestering its biological
function. Similarly, a polypeptide molecule which contributes to the canine NGF
antagonistic antibodies of the invention may be chemically modified with one or
more functional groups provided that such functional groups do not interfere with
the ability of the antibody or antibody fragment to bind to canine NGF and
antagonise its function.
As used , the term “effective amount” or “therapeutically effective ”
means the amount of an agent, binding compound, small molecule, fusion protein
or peptidomimetic of the invention which is required to suppress canine NGF
g to the p75 and/or TrkA receptors.
The terms "polypeptide", "peptide", or "protein" are used interchangeably herein to
designate a linear series of amino acid residues connected one to the other by
peptide bonds n the alpha-amino and carboxy groups of adjacent residues.
The amino acid residues are usually in the natural "L" isomeric form. However,
residues in the "D" isomeric form can be substituted for any L-amino acid residue,
as long as the desired functional property is retained by the polypeptide.
As herein d an "antibody" encompasses antigen-binding proteins which
specifically bind to a target antigen of interest, in this case canine nerve growth
factor, having one or more polypeptides that can be recombinantly prepared or
which are cally encodable by immunoglobulin genes, or fragments of
immunoglobulin genes. The term "antibody" encompasses monoclonal and
chimeric antibodies, in particular caninised antibodies, and further encompasses
polyclonal antibodies or antibodies of any class or subtype. An “antibody" further
extends to hybrid antibodies, bispecific antibodies, heteroantibodies and to
functional fragments thereof which retain antigen g.
The phrase "specifically binds to" refers to the binding of an antibody to a specific
protein or target which is present amongst a heterogeneous population of ns.
Hence, when present in specific immunoassay conditions, the antibodies bind to a
particular protein, in this case canine NGF, and do not bind in a significant amount
to other proteins present in the sample.
As defined herein, a e” may also be ed to as a “dog”. Canines can be
categorised as belonging to the subspecies with the trinomial name Canis lupus
familiaris (Canis familiaris domesticus) or Canis lupus dingo. Canines include any
species of dog and includes both feral and pet varieties, the latter also being
referred to as companion s.
The present invention will now be described with nce to the following
examples which are provided for the purpose of ration and are not intended to
be construed as being limiting on the t invention. The methods and
techniques of the present ion are generally performed according to
conventional methods well known in the art and as described in various general
and more specific references that are cited and discussed throughout the present
specification unless otherwise indicated.
EXAMPLES
Example 1 — Production of antibodies
Whole antibody ces were produced by combining caninised variable
domain ces with C-terminal canine constant heavy or nt light chain
sequences. Four distinct immunoglobulin gamma (lgG) heavy chain nt
domain isotypes have been described in the canine immune system (Tang L. et al.
2001. Veterinary Immunology and lmmunopathology, 80. 259-270) along with
single kappa and lambda constant domain sequences.
The caninised qD11 VH domain was combined with each of the four lgG heavy
chain isotypes A, B, C and D and the caninised qD11 VL domain with the canine
kappa light chain constant . The sequences of the full-length mature
antibody chains (caN) are shown in SEQ ID 5 (VL1 and canine kappa constant
domain), 6 (VH1 and heavy chain isotype A), 7 (VH1 and heavy chain isotype B),
8 (VH1 and heavy chain isotype C) and 9 (VH1 and heavy chain isotype D). The
sequence of a light chain of a variant antibody (caN2) is shown in SEQ ID No:10
(light chain variant (VL2) and canine kappa constant domain). The amino acid
sequences for heavy chains of a variant antibody (caN2) are provided in SEQ ID
NO:11 (HCA variant — VH2 and heavy chain isotype A), SEQ ID NO:12 (HCB
variant — VH2 and heavy chain isotype B), SEQ ID NO:13 (HCC variant — VH2 and
heavy chain isotype C) and SEQ ID NO:14 (HCD variant — VH2 and heavy chain
isotype D).
The combined amino acid sequences were ted to expressible form in
mammalian cells by the optimal selection of codons and full al gene
synthesis and cloning into a mammalian cell expression vector pcDNA3.1+.
The resultant cDNAs were transfected into CHO cells and the supernatants from
heavy chains having the sequences SEQ ID NO:6-9 were analysed in Example 2.
Antibodies having the light chain sequence SEQ ID NO:10 and the heavy chain
sequence SEQ ID NO:11 were purified in Example 11.
Example 2 — ining binding of antibodies to murine and canine NGF
WO 53121
Combinations of caninised heavy and light chain cDNAs were transfected into
CHO cells, the supernatants harvested and reacted in ELISA format with either
canine or murine NGF. Following incubation and wash steps, the bound canine
antibody was detected by vity with a goat-anti canine lgG specific polyclonal
antibody linked to horseradish peroxidase (HRP) and developed using TMB. The
optical density of the resulting t was measured at 450nm and compared
with that from mock empty vector transfected supernatant (denoted as “Mock” in
Figure 1).
The results are shown in the graph of Figure 1. Binding to mouse NGF is shown
for 4 caninised antibodies. Each of these antibodies has the same light chain
(caN-kLC-1), that is a light chain comprising a canine kappa constant domain.
Each antibody has a different heavy chain constant domain. Accordingly a
specific heavy chain variable domain is combined with one of 4 different constant
domains (caN-HCA, caN-HCB, caN-HCC or caN-HCD). In the second part of the
graph, g of a single antibody comprised of the caN-kLC-1 light chain and the
caN-HCB nt chain to canine NGF is shown.
Example 3 — Purification of caninised antibodies
The supernatants obtained from Example 2 were purified using a Protein A
column, separated by SDS—PAGE and tested for reactivity to the anti-canine lgG
polyclonal antibody HRP. This polyclonal antibody preferentially recognises the
heavy chains.
The results are shown in Figure 2 A-D. Legend: A - HCA is a caninised antibody
comprising the caN-HCA heavy chain and caN-kLC light chain, HCB is a sed
dy comprising the caN-HCB heavy chain and the caN-kLC light chain, C -
HCC is a caninised antibody comprising the caN-HCC heavy chain and a caN-kLC
light chain, D - HCD is a sed antibody comprising the caN-HCA heavy chain
and a C light chain. With each of Figures 2A-D, L means load, W means
wash, P means peak on, and F means flow through.
It can be seen that Protein A entially binds to the H08 e (Le. a
caninised antibody sing the caN-HCB heavy chain), whereas significant
material is not retained and is easily washed off of Protein A by the HCA, H00 and
HCD isotypes.
Example 4 — Analysis of purified caninised antibodies using SDS—PAGE
entative fractions of the peaks from the gels shown in Example 2 (Figures
2A-D) were separated by SDS—PAGE and stained with Coomassie blue.
The results are shown in the gel shown in Figure 3. This gel shows that heavy
and light chains are clearly e. Order of lanes from left: Lane 1 - Size
standards, Lane 2 - HCA caN-HCA + caN-kLC1, Lane 3 - HCB caN-HCB + caN-
kLC1, Lane 4 - HCC caN-HCC + caN-kLC1, Lane 5 - HCD caN-HCA + caN-kLC.
Example 5 - Inhibition of NGF induced proliferation of TF-1 cells by caninised
antibodies
Serial dilutions of CHO cell ectant supernatants from Example 2
(“antagonist”) were incubated with TF-1 cells in the presence of 0.3 ng/mL NGF.
The resultant proliferation was measured by thymidine incorporation.
The results are shown in Figure 4. 50% inhibition was observed at a calculated
0.75- 1.5 ng/mL monoclonal antibody (MAb).
e 6 - Complement deposition induced by antigen-captured caninised
antibodies
CHO cell transfectant supernatants from Example 2 were incubated with plates
coated with 0.1 ng/mL NGF to capture the antibodies. The plates were washed
and then incubated with human serum and bound complement C1q was measured
by binding of anti-human C1q polyclonal antibody HRP and developed as above.
Complement Binding Method
Plates were coated with 100 ul/well of 5 ug/ml mouse NGF and blocked with 5%
BSA/PBS. Coated wells were incubated for 1 hour at room temperature with cell
e supernatants, containing recombinant caninised anti-NGF lgG, diluted in
PBS/1% BSA (100 ul/well). The plates were washed and incubated for 1 hour at
room temperature with 100 ul/well of human serum diluted 1/100 in veronal
buffered saline containing 0.5 mM M9012, 2 mM 08012, 0.05% Tween-20, 0.1%
n and 0.5% BSA. After g, plates were incubated with 100 pl of a 1/800
dilution of sheep anti-C1q-HRP (Serotec) in PBS/1% BSA. After washing, plates
were developed by the on of 100ul TMB substrate (Thermo Scientific).
Development was stopped by the addition of 100 pl of 2N H2804 and absorbance
read at 450 nm.
The results are shown in the graph of Figure 5. These results show binding of
C1q to immobilised caninised HCB and HCC type antibodies and no binding of
C1q to caninised HCA and HCD type antibodies. Hence, the results singly
indicate that different canine derived heavy chains exhibit different complement
binding and activation teristics and that the caninised antibodies with type
HCA and HCD heavy chains have been unexpectedly shown to be preferable for
use in antagonising canine NGF. The identification of canine derived heavy
chains which do not mediate complement fixing is a particularly advantageous
finding as NGF is a soluble mediator.
Example 7 — Comparison of the g of anti-canine-NGF onal
antibodies to NGF
A comparison of the binding of anine-NGF monoclonal antibodies to NGF
using orks VL1 and VH1 (SEQ ID NO:1 and 2) versus alternate
frameworks VL2 and VH2 (SEQ ID NO:3 and 4) was carried out. DNA encoding
the light and heavy chains described by SEQ ID NO:10 and SEQ ID NO:11 were
synthesised and cloned into pcDNA3.1+ downstream of secretory signal sequence
peptides. The DNAs were co-transfected into CHO cells and the supernatant
compared by binding ELISA to mouse NGF with CHO supernatant from co-
expression of SEQ ID NO:5 plus SEQ ID NO:7.
The results are shown in Figure 13A. Lanes A-D show supernatant uted,
1/10, 1/100, 1/1000 respectively) from SEQ ID NO:5 and SEQ ID NO:7. Lanes E-
H show supernatant (undiluted, 1/10, 1/100, 1/1000 respectively) fromSEQ ID
NO:10 and SEQ ID NO:11. Lane I shows an undiluted ve l
supernatant.
Example 8 - ment deposition induced by ptured caninised
antibodies
CHO cell transfectant supernatants from Example 7 were tested for their ability to
recruit complement using a C1q ELISA assay (using the method described in
Figure 5).
The results are shown in Figure 138. The combination of VL2 (in SEQ ID 10) and
VH2 frameworks plus HCA type nt domains (SEQ ID 11)was inactive at
recruiting complement despite equivalent binding to NGF observed in Panel A to
that of the HCB type heavy chain in MAb (SEQ ID 5+7). The MAbs were tested in
a dilution series of 4, 2 and 1 ug/ml. C was a negative control.
Example 9 - Comparison of binding to NGF of N-glycosylated and aglycosylated
variants of anti-canine-NGF monoclonal antibodies with HCB and HCC heavy
chain es
A comparison of the binding of N-glycosylated and aglycosylated variants of anti-
canine-NGF monoclonal antibodies to NGF with HCB and HCC heavy chain
isotypes was carried out. Expression vectors encoding the light and heavy chain
pairs described by SEQ ID NO:5 and SEQ ID NO:7 (HCB), SEQ ID NO:5 and SEQ
ID NO:16 (HCB*), SEQ ID NO:5 and SEQ ID NO:8 (HCC), or SEQ ID NO:5 and
SEQ ID NO:1? (HCC*) were co-transfected into CHO cells and the supernatants
compared by binding ELISA to mouse NGF.
The results are shown in Figure 14A . The white boxes show undiluted
supernatant, the shaded boxes show a 1/100 dilution and C shows an undiluted
negative control supernatant. Equivalent binding to NGF was observed.
Example 10 - Complement deposition d by NGF-captured sed
dies
CHO cell transfectant supernatants from Example 9 were tested for their ability to
recruit complement using a C1q ELISA assay (using the method described in
Figure 5).
The results are shown in Figure 148. The ability to recruit ment C1q was
abolished by removal of the N-linked glycosylation site in the B type heavy chain
(HCB*) and was diminished by a similar mutation in the C type heavy chain
(HCC*).
Accordingly, it is demonstrated herein, quite surprisingly, that where an antibody of
the invention has a canine derived heavy chain of the HCA or HCD subtype, the
binding of the antibody to canine NGF does not result in complement activation or
other downstream effector functions, such as ADCC. Hence, said antibodies, in
antagonising the biological onal activity of canine NGF by preventing binding
of canine NGF to the membrane bound TrkA or p75 receptors, inhibit the
associated downstream intracellular signalling cascade. Furthermore, as NGF
expression frequently occurs in the ity of nerves and the like, the NGF
antagonising or lising antibodies of the invention, which have canine derived
heavy chain of the HCA or HCD subtype, can sequester canine NGF biological
activity t recruiting a wider immune response. Such functional properties
are unexpected, yet highly desirable.
Example 11: Purification of anti-NGF monoclonal antibodies following expression
in CHO cells
Since canine anti-NGF monoclonal dies of the HCA and HCD isotypes have
desirable lack of binding to complement (Figure 5), but bind weakly to
Staphylococcus Protein A e 2), alternative methods of purification were
developed. Anti-canine NGF monoclonal antibodies derived from expression
vectors expressing SEQ ID NO:10 (light chain variant (VL2) and canine kappa
constant domain) and SEQ ID NO:11 (HCA variant — VH2 and heavy chain isotype
A) were expressed in CHO cells and following extensive experimentation it was
found that the canine anti-NGF antibody could be fractionated to high purity by two
alternative purification methods.
In the first method, anti-canine NGF monoclonal antibody was purified by anion
exchange chromatography, hobic interaction chromatography and size
exclusion chromatography (Method I - Figure 15A and B). In the second method,
the anti-NGF antibody could be ed by Captoadhere affinity chromatography
followed by anion ge chromatography (Method ll - Figure 150 and D).
The main peak of anti-NGF onal antibody purified by either method
corresponds to a molecular weight of approximately 150 kDa. Comparison by
GE and ELISA (Figure 16) illustrates that Methods I and II produce
antibody preparations with similar purity and bioactivity. Purified anti-NGF
monoclonal antibodies produced by these methods were tested in the TF-1 NGF
neutralisation assay (described in Figure 4) and shown to have high y (IC50
13 pM anti-NGF neutralised 37 pM NGF; not shown).
Example 12: Anti-canine NGF monoclonal antibodies can be safely administered
enously to canines and do not cause pyrexia
Anti-canine NGF monoclonal antibodies derived from expression vectors
expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain)
were expressed in CHO cells and purified by a combination of ion exchange
tography, hydrophobic interaction chromatography and size exclusion
chromatography (Method I, Figure 15A and B) and buffer exchanged into
phosphate buffered . The antibodies were injected intravenously into beagle
dogs at 2 mg/kg body weight and assessed for signs of toxicity by visual
inspection by a veterinarian, change in body weight, body temperature and plasma
biochemistry. Figure 17 illustrates the body weight and temperature
measurements. No s were observed in these or any plasma biochemistry
analyte measured (including , potassium, chloride, calcium, phosphate,
urea, creatinine, glucose, terol, bilirubin, alanine transaminase, alkaline
phosphatase, amylase, lipase, total protein or n: not shown).
e 13. Plasma pharmacokinetics of anti-canine NGF monoclonal antibodies
in vivo demonstrates long serum half-life and lack of immunogenicity
anine NGF monoclonal antibodies derived from sion vectors
expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain)
were expressed in CHO cells and ed by a combination of ion ge
chromatography, hydrophobic interaction chromatography and size exclusion
chromatography and buffer exchanged into phosphate buffered saline d 1,
Figure 15A and B). The antibodies were injected intravenously into beagle dogs at
2 mg/kg body weight and plasma samples were taken at various times over the
following 2 weeks. Diluted plasma s were assessed for anti-canine NGF
antibody concentration by ELISA using NGF as target and anti-canine polyclonal
antibody-horseradish peroxidase secondary reagent and developed as per Figure
1. The results are shown in Figure 18. The plasma concentrations measured
were consistent with two-phase kinetics, with a tissue distribution (alpha) phase
half-life of approximately 33 hours and surprisingly long elimination (beta) phase of
approximately 9 days.
The absence of a sharp decline in plasma concentration of anti-canine NGF
antibody concentration between 100 and 300 hours trates that there are
neither pre-existing neutralising antibodies to recombinant anti-NGF monoclonal
antibodies in dog blood nor were any such neutralising antibodies generated
following infusion. By comparison, recombinant human immunoglobulin based
proteins are neutralised by antibodies in dog blood at approximately 200 hours
post infusion (Richter et al, Drug Metabolism and Disposition 27: 21, 1998). These
results therefore show that anti-canine NGF antibodies of the t invention
have a long serum half life (9 days) in vivo following intravenous injection and that
there are neither pre-existing antibodies nor newly generated antibodies that
neutralise the injected anti-NGF antibodies over time.
Example 14 — Effect of anine NGF monoclonal antibodies in reducing
inflammatory pain in vivo
Antibody therapy:
Anti-canine NGF monoclonal dies derived from expression vectors
expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain)
were sed in CHO cells and purified by a combination of ion exchange
chromatography, hydrophobic interaction chromatography and size exclusion
chromatography (Method I) and buffer exchanged into phosphate buffered saline.
Canine model of inflammation:
All experiments were carried out with prior approval of the utional Ethics
Committee (CRL, Ireland). Beagle dogs were injected (= day -1)with kaolin into
the footpad of one hind leg in order to generate a self-resolving inflammation
beginning approximately 24 hours later and which causes the dogs to become
temporarily lame. In this model, once the initial inflammation response to kaolin
recedes, the dogs become steadily less lame over the period of approximately 1-2
weeks and then make a full recovery.
Groups of 3 dogs were injected intravenously with either anti-canine NGF
monoclonal antibodies at 200 ug/kg body weight or phosphate buffered saline as
e control (= day 0). The dogs were assessed for lameness over 7 days by a
visual scoring method (score 0, no lameness (full weight bearing); score 1, slight
lameness (not full weight bearing but g well); score 2, moderate ss
(slightly weight bearing and not g well), score 3, severe lameness (not
weight g)). Observers were blinded to which dogs received which injection.
The results are shown in Figure 19. Lameness scores were reduced in the dogs
receiving anti-NGF monoclonal antibodies by day 3 post-injection compared with
vehicle control, indicating that the anti-NGF monoclonal antibodies had an effect in
reducing the pain in the dogs over that seen with vehicle alone. The d
activity is consistent with the plasma pharmacokinetics of anti-canine NGF
monoclonal antibodies which demonstrated a slow tissue distribution (alpha)
phase of approximately 30 hours and the relatively poor vascularisation of the
footpad area. The results shown in Figure 19 show that the anti-canine NGF
antibodies of the present invention reduce inflammatory pain in dogs with a
consequent reduction in lameness.
All nts referred to in this specification are herein incorporated by reference.
Various modifications and ions to the described embodiments of the
inventions will be apparent to those d in the art t departing from the
scope of the invention. gh the ion has been described in connection
with specific preferred embodiments, it should be understood that the ion as
claimed should not be unduly limited to such embodiments. Indeed, various
modifications of the described modes of carrying out the invention which are
obvious to those skilled in the art are intended to be covered by the present
invention.
Throughout this specification and the claims which follow, unless the context
requires otherwise, the word "comprise", and variations such as ises" and
"comprising", will be understood to imply the inclusion of a stated integer or step or
group of rs or steps but not the exclusion of any other integer or step or
group of integers or steps.
The reference in this specification to any prior publication (or information derived
from it), or to any matter which is known, is not, and should not be taken as an
acknowledgment or admission or any form of suggestion that that prior publication
(or information derived from it) or known matter forms part of the common general
knowledge in the field of endeavour to which this specification relates.
Claims (2)
1. A method of preparing an antibody le for use in a canine comprising: comparing (i) sequences of framework regions of a donor antibody from a species other than a canine, wherein the donor antibody has binding specificity for a target antigen present in canines with (ii) sequences of framework regions of one or more canine antibodies, and ing the framework regions of the donor antibody to substitute amino acid residues that are different at a corresponding position in the one or more canine antibodies with amino acid residues present at the corresponding position in the one or more canine antibodies to produce a modified antibody, wherein the modified antibody does not contain any amino acid in any position within the ork regions which would be n at that position in the one or more canine antibodies; and wherein the modified antibody is capable of specifically g to canine nerve growth factor (NGF) and inhibiting the ability of canine NGF to bind to the p75 or TrkA canine NGF or.
2. An antibody or an antigen binding fragment thereof which is capable of specifically binding to canine nerve growth factor (NGF) and inhibiting the y of canine NGF to bind to the p75 or TrkA canine NGF receptor, wherein the antibody or antigen binding fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 or an amino acid sequence which has an identity of at least 85% thereto and a heavy chain le region comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence which has an ty of at least 85% thereto, wherein the antibody or antigen binding fragment thereof does not n any amino acid in any position within the framework regions which would be foreign at the position in one or more canine antibodies.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483481P | 2011-05-06 | 2011-05-06 | |
US61/483,481 | 2011-05-06 | ||
GB1114858.2 | 2011-08-29 | ||
GBGB1114858.2A GB201114858D0 (en) | 2011-08-29 | 2011-08-29 | Anti-nerve growth factor antibodies and methods of using the same |
US201161531439P | 2011-09-06 | 2011-09-06 | |
US61/531,439 | 2011-09-06 | ||
PCT/GB2012/051002 WO2012153121A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617446A NZ617446A (en) | 2014-12-24 |
NZ617446B2 true NZ617446B2 (en) | 2015-03-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190161540A1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
US10040849B2 (en) | Caninized anti-nerve growth factor antibodies | |
US20190276525A1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
AU2012252152B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
CA2835094C (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
NZ617446B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
GB2528811A (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
EP4026845A1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
NZ617447B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
NZ617448B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |